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Abstract 
Background The grade IV glioma tumor Glioblastoma multiforme (GBM) arises from a 
normal brain tissue, grows rapidly and is highly malignant. GBM causes an increase of 
blood vessels around the tumor containing dead cells. GBMs are common diagnosed in 
adults especially men aged between 45 and 56 years. Since the major cause of most brain 
tumor is unidentified, it is important to study the genes that play a role in glioblastoma 
development, hence the need for gene expression profiling. Gene expression profiling 
helps to identify/reveal molecular classes, which can never be detected by looking at GBM 
samples under the microscope (American Brain Tumor Association, 2016).   
 
Aims: This study aims to use statistical methods on glioblastoma multiform (GBM) data 
obtained from microarray experiment to identify genes and samples subgroup, get 
differentially expressed genes, discover class membership, identify pathways, evaluate the 
aggressiveness of GBM sample groups and verify analysis outcome using an independent 
glioblastoma dataset. 
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Methods: The GBM data (Experimental data) used was obtained from The Cancer Genome 
Atlas (TCGA) via University of California Santa Cruz (UCSC) Genome browser as a zipped file 
that contains preprocessed data matrix, clinical data etc. The data matrix is used for class 
discovery, class comparison and class prediction analysis, while the clinical data is used for 
survival analysis. Samples subgroup, list of differentially expressed genes, sample 
membership, GBM aggressiveness prediction are results obtained from these analyses with 
the help of R and Biocondutor tools. In addition, biological interpretation is also one of the 
results obtained and it was done with PANTHER data analysis tool. PANTHER reveals the 
pathways and functional enrichment of the differentially expressed genes from 
experimental and validation datasets. Results from this study are validated with an 
independent GBM dataset (Validation data) obtained from Gene Expression Omnibus 
(GEO) by comparing the pathways and functional enrichment between the experimental 
dataset and the independent GBM dataset. 
 
Results: A correlation matrix is obtained after filtering and scaling the gene expression data 
matrix. This correlation matrix is plotted on the heatmap to show the relationships that 
exist between samples, and on dendrogram to show how samples are clustered into 
groups. Class comparison analysis produces a new data matrix, which contains as rows the 
differentially expressed genes, obtained between the sample groups (two sample groups) 
identified with clustering analysis, which appear as the matrix column. The differentially 
expressed genes are obtained with fold change and t-test analysis. The top 50 differentially 
expressed genes from the new data matrix are interpreted with PANTHER in order to 
discover molecular functions, biological processes, cellular components and pathways in 
which these genes are active. The Kaplan-Mier survival curve obtained from GBM clinical is 
generated to evaluate survival difference between classes. Comparing molecular functions, 
biological processes, cellular components and pathways in which DEGs from both datasets 
play significant roles helps in validating analysis results. 
 
Conclusion: Statistical methods are very important in analyzing microarray data since it 
gives insight into the data under study.  
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1. INTRODUCTION 
1.1 BACKGROUND TO THE STUDY 
Glioblastoma multiforme (GBM) is a grade IV glioma tumor, which arises from a normal 
brain tissue, grows rapidly and is highly malignant. There is an increase of blood vessels 
around GBM and it contains dead cells. GBMs are rare and most commonly occur in adults 
especially men aged between 45 to 65 years and very aggressive (American Brain Tumor 
Association, 2014). Been aggressive, it is important to predict the survival of patients with 
GBM. 
 
Since the major cause of most brain tumor is unidentified, it is important to study the 
genes that play different roles in the development of glioblastoma. Hence, gene expression 
profiling is essential. In addition, molecular classes which can never be the detected by 
looking at GBM samples under the microscope has been revealed by gene expression 
profiling (American Brain Tumor Association, 2014).  
 
In recent times, the advancement achieved in high-throughput microarrays has provided 
series of information relating to the biology behind glioma. Microarrays has helped to 
distinguish difference in the gene expression between normal and tumor (glioma) tissue 
(B.W. Kunkle et al 2013). Microarray experiment is a large-scale experiment that involves 
studying gene expression levels under a particular condition for thousand of genes 
concurrently. The process above is called gene expression analysis and sometimes referred 
to as gene expression profiling.  Microarray technology has become a vey important tools 
employed by biologists to study an organisms genome wide expression levels of gene. It 
should however be noted that microarray measures the expression of genes in many ways 
but it most popular application is to compare gene expression levels maintained between 
two conditions such as healthy versus normal (M.M. Babu, 2004). 
 
To achieve an outstanding results from microarray experiment we need to properly plan. A 
good plan will come in place if there are clear objectives, which must be able to answer 
biomedical questions before proceeding with the experiment. Hence, microarray 
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experiment objectives can be class comparism, class prediction and or class discovery. Class 
comparism involves identifying differentially expressed genes among predefined group of 
samples. Class prediction involves accurately predicting the biologic group a sample from a 
patient belongs based on the patient’s gene expression profile with the help of a classifier. 
Class discovery involves discovering samples or gene groups that are similar based on their 
gene expression profile (R. Simon, 2003). 
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2. LITERATURE REVIEW 
2.1   GLIOBLASTOMA MULTIFORME (GBM) 
Glioma is a tumor that emanates from glial or the supportive tissue of the brain. An 
example of glioma is astrocytoma. Astrocytoma grows from astrocytes, which are star-
shaped cells (American Brain Tumor Association, 2014). In addition, astrocytoma is the 
most common glioma with glioblastoma multiforme been their most threatening form. 
Researches conducted recently have helped to identify the basic biology behind GBM, 
though the major structure of the development of GBM remains unidentified. It has been 
difficult to understand the elementary molecular structure of pathophysiology that 
stimulates astrocytoma development and this has thus prevents the breakthrough that 
ought to have been achieved in astrocytoma treatment (B.W. Kunkle et al 2013). 
 
Glioblastoma multiforme (GBM) is a grade IV glioma tumor, which arises from a normal 
brain tissue, grows rapidly, highly malignant (American Brain Tumor Association, 2014) and 
destructive (C.V. Neubeck et al 2015). Glioblastoma multiforme is the aggregation of 
tumors that emerges from glia or their precursors inside the central nervous system. 
Gliomas are of four grades with glioblastoma multiforme (GBM) been the most threatening 
of the gliomas. Most of the patients with GMB find it difficult to survive the disease in a 
period beyond one year and importantly with short survival. This has thus made these 
tumors popular (E.C. Holland 2000). 
 
It is evident that lineage restricted progenitor and cells neural stem cells functions as the 
source of GBM or glioma-initiating cells (C.V. Neubeck et al 2015). It is a harsh brain cancer 
type defined by immense potential for growth and awful clinical result. It is an incurable 
form of cancer with a median survival of less than a year (M. Henriksen et al 2014). Since 
GBM occurs in different forms, necrosis and hemorrhage regions are excessively displayed. 
Also pleomorphic nuclei and cells, pseudopalisading necrosis and microvascular 
proliferation regions can be observed under the microscope. In addition, deletions, point 
mutations and amplification are also visible genetically in GBM, which leads to the 
amplification of signal transduction pathway activation downstream of platelet-derived 
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growth factor receptor (PDGFR) and epidermal growth factor receptor (EGFR) and cell cycle 
arrest pathway disruption by p53 mutations or INK4a-ARF loss (E.C. Holland 2000). 
 
2.1.1   OCCURRENCE OF GBM 
Glioblastoma multiforme (GBM) is a primary brain tumor that poses danger to life. It exists 
in 3 to 4 grown-up patients per 100,000 people living in Europe.  GBM occurs mostly in 
adults aged 50 and above and it affects male than female. In addition, close to 9% of brain 
tumors that affect children are GBM (X. Xu et al 2011).  
 
GBM is subdivided into primary and secondary. Primary GBM is also known as de novo 
GBM, they emerge quickly and their presence is easy to detect.  In addition, they are the 
most common and aggressive form of GBM and occur in individual aged 55 and above  
(American Brain Tumor Association, 2014). In primary GBM, about 40 to 60% of these 
GBMs are characterized by overexpression and genetic mutation of epidermal growth 
factor receptor (EGFR) and its gene, which consecutively result in mutated, form of EGFR 
(M. Henriksen et al 2014). Secondary GBM on the other hand arises as low-grade 
astrocytoma, which will later develop into dangerous and actively growing glioblastoma 
(American Brain Tumor Association, 2014). It is characterized by continuous accumulation 
of mutations in p53, growth factor derived from platelets, and retinoblastoma gene (M. 
Henriksen et al 2014). 
 
Furthermore, the larger parts of GBM emerge from primary glioblastoma while the 
remaining parts originate from lower grade astrocytoma. The molecular genetic differences 
between the benign minor astrocytoma (Grade I - II) and malignant major astrocytoma 
need to be determined so that characterization of these tumors can be achieved easily. 
Also, the genes and pathways involved in these tumor classes need to be determine so that 
better treatments could be provided for in years to come (B.W. Kunkle et al 2013).  
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2.1.2   CAUSE AND SYMPTONS GBM 
The major cause of GBM and other forms of brain tumor is still unidentified. In addition, 
most brain tumors are not hereditary but some can sometimes be induced by syndrome 
such as Neurofibromatosis, Li-Frameni, Von Hippel-Lindau, Turcot and Tuberous Sclerosis 
that are inherited genetically. The genetically inherited syndromes are present in small 
number of patients (say 5% or lower) having this tumor. In recent time, scientists have 
traced the major causes of glioblastoma to deformities in genes of various chromosomes, 
which may be involved in the tumor development. Although, the major cause of the 
deformities that occur in genes remains unclear (American Brain Tumor Association, 2014). 
 
The growth of this tumor in the brain causes a disruption of the brains normal function due 
to the fact that the skull size cannot be increased. This thus leads to increase pressure on 
brain, headache, seizures, loss of memory and behavioral changes. In addition, there is also 
loss in movement, cognitive deterioration and language dysfunction. Other symptoms are 
also possible depending on the size and location of the tumor in the brain (American Brain 
Tumor Association, 2014). 
 
2.1.3   BIOLOGY BEHIND GBM 
Over the last 20 years, knowledge of the molecular biology behind GBM has greatly 
advanced. Cells in GBM are subjected to different kind form cell deterioration, which 
makes them resistance to anti-GBM treatments. Intracellular events occur alongside tumor 
forming events and both together cause and sustain GBM (M. Nakada et al 2011).  
 
The first of these events is cell cycle control loss. Glioma cells create a means for escaping 
the strict control that regulates normal cell progression. This thus makes glioma cells to 
gain growth benefit, which in turn leads to genetic defect in growth regulatory molecules 
within the glioma cells. These defects are common in malignant gliomas compared to low-
grade gliomas. Alteration of at least one component of p16INK4a/cyclin-dependent kinase 
(CDK)-4/RB (retinoblastoma) 1 pathway, which is major pathways controlling G1–S phase 
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transition cell cycle checkpoint occur in several anaplastic astrocytomas and in the 
unlimited cases of GBMs (M. Nakada et al 2011). 
 
The second event that cause and sustain GBM is the overexpression of growth factors and 
their receptors. Glioma cells set up an autocrine growth-promoting loop because they 
express both growth factor ligands and their receptors. Epidermal growth factor receptor 
(EGFR), platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF, FGF-2), 
transforming growth factor (TGF)-α, and insulin-like growth factor (IGF)-1 are the growth 
factors that are overexpressed in GBM and they thus gives merits to neoplastic cells. 
Among the growth factors overexpressed in GBM, EGFR and PDGF are the most common 
(M. Nakada et al 2011).  
 
Another event that play role in the cause and sustenance of GBM is angiogenesis. In GBM 
progression, sequence of angiogenic alterations appears like a ring-like contrast 
enhancement around the rapidly growing tumor. These alterations are seen to surround he 
tumor when viewed Magnetic Resonance Imaging (MRI) scan. Angiogenic molecules are 
present in malignant glioma especially GBMs. This is because malignant gliomas are 
vascular tumors of high grades as a result microvascular proliferation (M. Nakada et al 
2011). 
 
Invasion and migration is also a key feature that cause and sustain GBMs. Invasion and 
migration are influenced by expression of many extracellular matrix (ECM) molecules and 
cell surface receptors and this causes GBM to diffuse into their surrounding neural net (M. 
Nakada et al 2011). 
 
Another event that create and sustain GBMs is abnormality in apoptosis. Apoptosis also 
known as cell death is usually characterized by non-inflammatory cellular condensation and 
it takes place in a programmed manner. Cells in glioma develop means for increased 
reproduction and to annul apoptosis. Mutation in p53 affects apoptotic response in normal 
glial, which normally accompany growth factor overexpression in low-grade glioma (M. 
Nakada et al 2011). 
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Genomic instability also plays a vital role in the cause and sustenance of GBM. Low-grade 
glioma progress to high-grade lesions quickly and such progression is related to the 
development of malignant clones. Many malignant clones are selected when genomic 
dame occurs as a result of genomic instability. Genomic instability causes tumor 
progression in genome with mutation in p53 genes (M. Nakada et al 2011). 
 
2.1.4   PROGNOSIS AND TREATMENT OF GBM 
Before the tumor can be treated, a proper diagnosis needs to be conducted on patients 
suspected of having this tumor. Diagnosis is commenced by first carrying out a neurological 
examination on the patient followed by a Magnetic Resonance Imaging (MRI), Computed 
Tomography (CT) or Magnetic Resonance Spectroscopy (MRS) scan. This scan thus helps to 
determine the location, size, tumor type and mineral and chemical level in the tumor, 
which in turn revealed whether the tumor is benign or malignant and also to know whether 
the patient has tumor or not (American Brain Tumor Association, 2014). 
 
GBM is a tumor with complex characteristics, among which is the presence of subclones 
within the tumor cell population that makes the tumor to be genetically heterogeneous. 
Their complex characteristic has made them resistant to treatment interventions. For 
years, the conventional method of treating GBM has remained unchanged. Firstly a surgery 
is carried out on the patient in order to get rid of tumor, secondly is radiation therapy and 
lastly is chemotherapy. In most conditions, the mean survival of the patients with this 
disease only increases with just 9 to 10 months even after all the tumor seen on MRI scan 
has been surgically removed and the patients are fully treated with radiation and 
chemotherapy. This is so because the disease is diffuse topographically making the tumor 
and its location variable, which leads in improper resection of the tumor (E.C. Holland 
2000).  It is impossible to have a gross total resection without neurological and functional 
impairments such as motoric disorders, which thus have an adverse effect on quality of life 
(C.V. Neubeck et al 2015).  
Before the last 10 years, the outcome of patents with GBM has been slightly improved 
despite the improvement in technology achieved in surgery, radiotherapy and also in 
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chemotherapy development. Despite applying intense treatments applied to GBM, it shows 
resistance to multimodal therapy and its survival time is still reported in months. The 
current method employed in treating GBM was proposed by the European Organization for 
Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical 
Trials Group (NCIC). This method involves surgery carried out to remove all tumors 
(debulking surgery) accompanied by fractionated radiotherapy alongside concomitant and 
adjuvant treatment of the cytostatic agent temozolomide (TMZ). This method has thus 
increased the median and the 2 years survival of patients with this disease to 14.6 months 
and 26.5% compared to the median and 2 years survival of patients treated with only 
radiotherapy, which is 12.1 months and 10.4% (C.V. Neubeck et al 2015). 
 
2.2   RNA SEQUENCING VERSUS MICROARRAY IN GENE EXPRESSION PROFILING 
An organism’s transcriptome defines the whole range of transcripts present in that 
organism. The genes encode these transcripts as a phenotypic reply to the condition in 
which they occur.  The ability to quantify the expression of thousand of genes at the same 
time has changed the face of biomedical research and this enables the analysis of gene 
expression pattern at a genome-wide scale. In the past 10 years, there has been a huge 
advancement in the improvement of methods used for analyzing and quantifying the 
expression level of gene transcriptome wise. RNA-seq and DNA microarray are exceptional 
and are the two most commonly used method for genome-wide gene expression 
quantification among the transcriptome profiling methods (S. Kogenaru et al 2012).  
 
In RNA-seq, isolated transcripts are first converted into complementary DNA (cDNA). The 
resulting cDNA are then sequenced with a massive deep-sequencing approach. The gene 
expression levels in relation to the condition of interest or absolute level are quantified by 
mapping the resulting short sequencing reads to the reference genome.  RNA-seq can be 
carried out on different platforms such as Illumina’s Genome Analyzer, Roche 454 Genome 
Sequence, and Applied Biosystems’ SOLiD. On the contrary, specimen target strands are 
hybridized unto the fastened complementary probe strands in microarray.  In a two-color 
microarray, the extracted transcript from different conditions are labeled with specific 
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fluorescent dyes and converted to cDNA. The labeled transcripts are however hybridized to 
the fastened complementary probe strands in an array depicting the genes.  The relative 
abundance of each transcript in the two different conditions is determined by measuring 
the intensity of light from the specific fluorescent dye. Microarray can be carried out on 
Affymetrix and Agilent platforms, which are the two common microarray technology 
platforms (S. Kogenaru et al 2012). 
 
Recent literatures have compared two of the most widely used gene expression profiling 
method namely, gene expression microarray and RNA-seq documenting the utility and 
reproducibility of these methods. It is important to understand gene expression control as 
this makes understanding the relationship that exists between phenotype and genotype 
possible.  Scientist developed DNA microarray technology with the aim of assessing 
transcript abundance in biological sample reliably. However, RNA-seq gives a more 
accurate measurement and absolute transcript abundance (K.J Mantione et al 2014).  
 
Over the past 10 years, the analysis of microarray data has become easier for a beginner. 
The software packages used in analyzing microarray data are user friendly with most of 
them available for free. The protocols in each of these packages are universally applicable 
and can be compared across platforms. On the contrary, there are many data analysis 
method available in RNA-seq each with different protocols. The analysis of data from RNA-
seq requires broad experience and bioinformatics skills required in processing the data 
files. The techniques used in analyzing data from RNA-seq differ in both the software 
employed for data transformation and different RNA-seq experiments. Data sharing and 
storage in RNA-seq is extremely difficult because an unprocessed RNA-Seq raw file is 
approximately 5GB compare to microarray with an unprocessed raw data of 0.7MB (K.J 
Mantione et al 2014). 
 
In conclusion, the complex nature of data from RNA-seq will be reduced due to 
advancement in software and invention of newer techniques. Also the cost of running RNA-
sequencing experiment will also drop with time. However, presently, it is more dependable 
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and cheaper to use microarray for gene-expression profiling in model organism compared 
with RNA-seq. In addition, gene expression microarray quickly and easily gives unique, 
useful and hidden information from examining the gene expression patterns across large 
number of samples. Microarrays has been used for clinical application for a longer period 
and might obtain regulatory approval for diagnostics purposes before RNA-seq gets its 
approval. In the future, RNA-seq will replace microarray but presently both techniques can 
complement each other (K.J Mantione et al 2014). 
 
2.2.1   MICROARRAY 
Microarrays give a good approach in understanding gene expression analysis that can be 
used for different experimental purposes. It has thus helped researchers to perform 
experiments that are impossible few years back, gives distinctive challenges in data analysis 
and experimental design (S. A. Ness 2006). 
 
Microarrays are devices that identify and quantify the amount of mRNA transcript available 
in a cell (A. Sánchez and M. C. Ruíz de Villa 2008). They are usually made of glass slide, 
silicon chip or nylon membrane on to which DNA molecules are settled in a precise way at 
particular areas called spots. They may contain huge number of spots and every spot in 
turn contains a couple of million duplicates of indistinguishable genomic DNA molecule 
that compare to a gene (M.M. Babu 2004). These spots could also contain cDNAs, PCR 
products or chemically synthesized oligonucleotide that interestingly compare to a gene.  
Spots in microarrays are imprinted on to the glass slide by a robot or are blended by the 
procedure of photolithography and are called probes (London school of Hygiene and 
Tropical medicine 2016).  
 
Furthermore, microarrays plays roles in events like gene transcription, protein coding, 
mutation detection, copy number variation, and DNA methylation by measuring them and 
identifying where such event occurs in the human genome (C. Seidel 2008). It examines at 
the same time the expressions levels of more that hundreds of genes, gene relationship, 
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functions of genes and gene/samples classification in reply to some biological disorder (E. 
Naghieh and Y. Peng 2006).  
 
2.2.1.1   MICROARRAY EXPERIMENT 
Microarray experiments are very robust and it equips researchers with new and old 
methods of solving problems pan-genomic. Since microarrays contains probes for 
thousands of different genes, researchers can assess changes in all the genes in the 
genome simultaneously. However this experiment is very expensive, consumes time, 
complicated, and gives large and complex dataset that requires a lot of effort to analyze 
and validate. Hence, microarray experiment should not be performed without the 
researcher considering other options and checking for the right experimental design. New 
microarray users are however advised to consult with their domestic microarray main 
facility before preparing samples for the microarray experiment (S.A. Ness 2006). The steps 
involved in microarray experiment are as follow 
 
A. TARGET EXTRACTION 
mRNA is extracted from cells or tissues grown in two condition such that A is the reference 
condition, B is the test condition (M.M. Babu 2004). The mRNA in this case is called a target 
(A.D. Tarca et al. 2006, D.P. Berrar et al. 2003). 
 
B. TRANSCRIBTION AND LABELLING 
The mRNA molecules in the extract are transcribed in a reversed manner into cDNA and 
labeled with fluorescent dyes. Label the cDNA from the cell grown in condition A with red 
dye and that from condition B with blue dye (M.M. Babu 2004). 
 
C. HYBRIDIZATION 
Differentially labeled samples are allowed to hybridize onto the same glass slide. The cDNA 
sequences in the sample thus hybridize to spots on the slide that contains their 
complementary sequence. The number of cDNA attached to a particular spot is 
proportional to the original amount of RNA molecules for the gene in question in both 
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samples (M.M. Babu 2004). The hybridization step is done with great care in order to 
minimize cross-hybridization between genes that are similar (A.L. Tarca et al. 2006). After 
completing the hybridization reaction, target and any reference materials that couldn’t find 
a probe partner are washed off (D.P. Berrar et al. 2003). 
 
D.   SCANNING 
The hybridized spot in the microarray are excited by a laser and scanned in order to 
identify the red and the green dyes. The amount of florescent that is emitted after 
excitation is proportional to the amount of nucleic acid that is bounded (M.M. Babu 2004). 
 
E.   DETECT AND EVALUATE mRNA ABUNDANCE 
After the scanning process, we obtain an image, which contain spots that compare to a 
gene  (M.M. Babu 2004). The image obtained is stored as a 16-bit tagged image file format 
(TIFF) file, which are in pairs and each fluorescent dye corresponds to one TIFF file (S. 
Dudoit et al. 2002). 
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Figure 2.1: (A) A microarray (B) Steps in microarray experiment (Figure adapted from M.M 
Babu, 2004) 
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2.2.1.2   WHY MICROARRAY EXPERIMENT 
Microarray experiment can be carried for the following reasons 
 
A.   Comparing patient samples 
Microarray experiment helps to compare gene expression profiles of leukemia samples 
from patients in order to identify samples that might respond to a particular type of 
treatment or to identify the likely cause of the disease in question (S.A. Ness 2006). 
 
B.   Genetic difference analysis 
Here microarray experiment are used to compare genetic expression pattern changes in 
the cell of an organism with the same genetic makeup (isogenic organism) which differs by 
mutation or overexpression of genes at particular gene location (S.A. Ness 2006). 
 
C.   Comparing treatment 
The comparism of a cell line before or after some defined treatment is applied to a 
particular disease can be studied with the aid of a microarray experiment. Here, we expect 
the cell line to behave in a certain way after the treatment and as a result this type of study 
is easy and straightforward (S.A. Ness 2006). 
 
2.3   TYPES OF MICROARRAY 
Microarray can be classified by probe length, method of manufacturing and number of 
samples profiled on one array (A.L. Tarca et al. 2006). 
 
2.3.1   PROBE LENGTH 
Array can be classified according to the length of its probe as: 
 
A.   Complementary DNA (cDNA) arrays 
This array uses long probes with length up to hundreds or thousand base pairs (A.L. Tarca 
et al. 2006). Due to their long length, cDNA array might detect the entire transcript 
produced through different RNA splicing. This array type is quite cheaper with robust 
hybridization. Its major disadvantages are high cost and it produces large libraries of 
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purified cDNAs that are always difficult to assemble (S.A. Ness, 2006). This type of array has 
a lot of variability in its design, more flexible, and easier to analyze with appropriate 
experimental design (S. Drăghici 2011).  
 
B.   Oligonucleotide arrays 
The probes here are short with length of 50 base pairs or less (A.L. Tarca et al. 2006). This 
array gives reliable data than cDNA array, which are prone to specificity and G-C content 
problems. This array type is however expensive and has reduced hybridization efficiency 
(S.A. Ness 2006). 
 
2.3.2   METHOD OF MANUFACTURING 
Arrays are either manufactured by deposition or in-situ. 
 
2.3.2.1   DEPOSITION APPROACH 
This method of manufacturing microarray involves depositing spots of ante-synthesized 
nucleic acid on array support surface (S. Drăghici 2011). This can be  
 
A. Deposition of PCR-amplified cDNA clones 
Here, DNA is prepared at a distance from the chip. Thin pins are the dipped into the DNA 
material with the aid of robots and the pins are touched onto the array surface. A spot is 
then formed which results from the deposition of small DNA quantity on the array surface 
(S. Drăghici 2011). 
 
B. Printing of synthesized oligonucleotides 
Here, short, synthesized oligonucleotides are attached to the solid support.  Since the 
probes used are short, the detection of splice variants is possible. This approach is called 
printed microarray (S. Drăghici 2011). 
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2.3.2.2   IN-SITU SYNTHESIS APPROACH 
This method of manufacturing microarray involves photo-chemically synthesizing the 
probes on the chips.  Probes are selected based on sequence information and hence each 
of the synthesized probes is recognized. This method monitors and differentiates genes 
that are related since it can avoid sequences that are identical among gene family 
members. Also this method does not introduce noise into the cDNA system, as there are no 
cloning, PCR reaction and spotting (S. Drăghici 2011). The approaches in this method are 
 
A.   Photolithographic approach 
This approach uses a photolithographic mask for each probe. This mask however has a hole 
that takes in a probe with a given base. The next masks will the construct the sequences 
base by base. This approach thus produces arrays of very high densities but the DNA 
sequences constructed has limited length. Examples of array produce with this method are 
Affymetrix, Santa Clara, CA etc. (S. Drăghici 2011). 
 
B.   Ink-jet technology 
This approach utilizes the technology used in ink-jet color printer. Cartridges are loaded 
with A, C, G and T nucleotides. Nucleotide deposition occurs when print head moves across 
the array substrate. Examples of array that uses this method are Agilent, Protogene etc. (S. 
Drăghici 2011). This method is thus fast, versatile and high yielding but gives a low 
resolution (R.D. Egeland and E.M. Southern 2005). 
 
C.   Electrochemical synthesis 
This method makes use of small electrodes, which are planted into the microarray 
substrate in order to control individual reaction sites. These electrodes are activated in the 
required positions in a fixed sequence after solutions with specific bases are washed over 
the substrate. This will thus construct the required sequences base wise. Examples of 
arrays here are CombiMatrix, WA, Mukilteo, Bothel  (S. Drăghici 2011).  
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2.3.3   NUMBER OF SAMPLES PROFILED ON ONE ARRAY 
Another array classification is based on the number of samples that can be profiled on one 
array. This can be  
 
A.   Single-channel array 
This is a type of array in which one sample is hybridized at a time and it is less common (J. 
Kesseli 2015). 
 
B. Multi-channel array    
Also called two-channel array, it hybridizes two sample at a time with each of the sample 
having is own fluorescent dye. The fluorescent dye thus allows the separation of the 
samples. This type of array is common in microarray experiments (J. Kesseli 2015). 
 
2.4   APPLICATIONS OF MICROARRAYS 
Microarray finds applications in the following areas  
 
2.4.1   DIFFERENTIAL GENE EXPRESSION ANALYSIS 
This analysis involves comparing gene expression levels between different experimental 
conditions say phenotypes i.e. comparing the expression discrepancy of a single gene 
expression profile against the experimental conditions. It usually considers one sample as 
the control or reference and the other sample as the experiment. Examples are healthy 
versus disease, treated versus untreated etc. (D.P. Berrar et al. 2003). 
 
2.4.2   CO-REGULATION OF GENES ANALYSIS 
This analysis involves comparing gene profiles of two or more genes with the purpose of 
identifying genes which expression measures differs in a corresponding manner throughout 
the experimental conditions.  Two genes are said to co-regulate positively if the expression 
measure of one gene increases as that of the other and co-regulate negatively if the 
expression measure of one gene decreases as that of the other (D.P. Berrar et al. 2003). 
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2.4.3   GENE FUNCTION IDENTIFICATION  
The function of a unique gene can be obtained from a detailed microarray experiment. This 
is done by comparing the expression profiles of previously studied genes with known 
function with that of the unique gene’s expression profile under different conditions. The 
functions of the previously studied genes with highly similar expression profile can be used 
to predict the functions of the unique gene in question (D.P. Berrar et al. 2003). 
 
2.4.4   PATHWAYS AND GENE REGULATORY NETWORK IDENTIFICATION 
Microarray experiment helps to identify pathways and genes regulatory network when a 
cell is stimulated by finding genes that are turned on and off at different time points. 
Pathway identification analysis helps to show the paths and procedures where genes and 
their products function in cell, tissue and organism while gene regulatory network 
regulates gene expression (D.P. Berrar et al. 2003). 
 
2.4.5   SEQUENCE VARIATION STUDIES 
Microarray experiments also helps to study variations that occur in sequences. Sequence 
variation studies aims to uncover DNA sequence variations that corresponds with change in 
phenotype e.g. diseases. Examples of sequence variation can be single nucleotide 
polymorphism (SNP), insertions and deletion etc. (D.P. Berrar et al. 2003). 
 
2.4.6   CLINICAL DIAGNOSTICS 
Microarray also finds application in clinical diagnostics where it helps to reveal the different 
pattern in expression measures that are feature for a particular type of disease and also to 
deduce unknown disease subtypes from previously known diseases (D.P. Berrar et al. 
2003). 
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2.5 ISSUES WITH MICROARRAY ANALYSIS 
The major issues associated with microarray user are as follows 
 
A. NOISE 
Noise is one of the major issues associated with microarray experiment because it is 
introduced at every step in the experiment. Since microarrays are noisy, repeating an 
experiment more than once using the same materials and same preparations as done in 
the previous experiment, many genes gives different quantification values after scanning 
and image processing steps as a result of noise (S. Drăghici 2011). 
 
B. EXPERIMENTAL DESIGN  
Experimental design is the most important phase microarray analysis process but      
frequently ignored. It refers to the test or series of tests that a scientist influences the input 
variable of a process with the aim of detecting and recognizing the effect that change has 
on the process outcome. If the microarray experiment to be carried out is not well 
designed, then the experiment will give a false result (S. Drăghici 2011). 
 
C. HUGE NUMBER OF GENES 
The microarray technology is capable of examining thousands of genes at the same time. 
When the number of genes is too large say tens of thousand in a microarray experiment,  
experimental quality and designed method might change and this might lead to a problem 
in the analysis process (S. Drăghici 2011). 
 
D. ASSESSMENT OF ARRAY QUALITY 
Assessing the quality of array should be the aims of the data analysis process in a 
microarray experiment. This assessment thus helps in rejecting the data from faulty array 
and to determine why a microarray process may fail. Hence it is very important and if not 
giving proper attention, might after result from the experiment (S. Drăghici 2011). 
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2.6   MICROARRAY ANALYSIS PROCESS 
The processes involved in microarray analysis are shown in the figure 2.2 below 
 
 
 
 
Figure 2.2: Microarray analysis processes (Figure adapted from A. Sánchez and M. C. Ruíz 
de Villa 2008). 
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2.6.1   BIOLOGICAL QUESTIONS 
This is the first phase of microarray analysis process, which tends to define the         
 biological effect of the microarray experiment we are about to start. Here we  
 formulate hypothesis and we check relevant literatures that will back the biological       
 findings we intend to make (D.P. Berrar 2003). 
 
2.6.2   EXPERIMENTAL DESIGN 
Experimental design is the most important phase microarray analysis process but      
frequently ignored. It refers to the test or series of tests that a scientist influences the input 
variable of a process with the aim of detecting and recognizing the effect that change has 
on the process outcome. To obtain a viable conclusion, experiment must be properly 
designed (S. Drăghici 2011).  For a successful experiment, the following should be consider 
 
2.6.2.1   EXPERIMENTAL DESIGN PRINCIPLES 
This refers to the rules which when adapted, leads to a successful experiment. The rules 
are replication, randomization and blocking. 
 
A. Replication  
It is a process of repeating an experiment more than once. If introduced in a microarray 
experiment, it helps to recognize and limit the noise introduced in the hybridization step of 
the microarray experiment and to constrain biological variability (S. Drăghici 2011). In a 
microarray experiment, replication can be technical or biological replication (A. Sánchez 
and M. C. Ruíz de Villa 2008). 
 
B. Randomization  
Randomization is a process of using a random choice for all factors that are unimportant 
but can have influent the experimental result. This can be done in microarray analysis 
process by printing replicated spot at random location throughout the array or by using 
different batches of microarray slide in differential gene expression (i.e. comparing a 
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reference group versus a treatment group). It thus helps to deal with nuisance factors (S. 
Drăghici 2011). 
 
C. Blocking  
This is a technique of creating similar microarray slides of data in which factor of interest is 
left to vary while nuisance factor is kept constant.  It helps to remove variability due to the 
difference between microarray slides (S. Drăghici 2011). 
 
2.6.2.2   EXPERIMENTAL DESIGN GUIDELINES 
When panning a microarray experiment, the following can be taken into account:  
i. Define research problem 
ii. Select the type of microarray to be used. 
iii. Seek experts opinion on experimental design and data analysis 
iv. Choose factors of interest in according to level of importance 
v. Identify possible nuisance factors 
vi. Choose significance level and desired power 
vii. Design your experiment 
viii. Execute the experiment and collect data 
ix. Analyze data 
x. Extract biological meaning from data analytics result (S. Drăghici 2011). 
 
2.6.3   MICROARRAY EXPERIMENT 
The steps involved in microarray experiment have been described in in section 2.2.1.1. 
Once the experiment as been performed, we proceed to the next step in the analysis 
process. 
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2.6.4   IMAGE ANALYSIS 
Image analysis involves measuring spots intensities and calculating gene expression values 
based on these intensities. This analysis assists in evaluating data reliability, helps to 
produce warning showing possible issues during hybridization and array production phases 
(S. Drăghici 2011). 
 
Furthermore, this analysis forms the basis of any further analysis as it represents the basic 
data collection step. The images from microarray experiment are seen as spots, which are 
arranged in an orderly manner into sub-grid and this orderly arrangement thus makes spot 
detection easy (M.M Babu 2004). The stages in image processing are explained in the 
subsections below. 
 
2.6.4.1   SPOT DETECTION 
This stage involves detecting signal spots in the images and computing the size of each 
spot. The method employed for spot detection can be manual, semiautomatics and 
automatic (S. Drăghici 2011). 
 
2.6.4.2   IMAGE SEGMENTATION 
This is a method of dividing image into regions, which do not overlap but whose unification 
represents the whole image. Segmentation aims to break the image down into spot and 
background in other to measure spot signal and evaluate the intensity of the background.  
Image segmentation step is introduced once the spot has been discovered, because it helps 
to determine which pixels represents the spot and should be used in signal calculation, 
which pixels represents the background and which pixel represents noise and should be 
removed. Segmentation methods can be pure spatial-based, intensity based, Mann-
Whitney, etc. (S. Drăghici 2011). 
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2.6.4.3   SPOT QUANTIFICATION 
Spot quantification involves calculating a unique value for each gene on the chip, which 
might be proportional to the quantity of mRNA present in the solution that hybridized the 
chip. It aims to marge pixel intensity values into a distinctive value that represents the 
expression level of a gene saved on each spot (S. Drăghici 2011). 
 
Spot quantification can be achieved by taking total, mean, median, mode, volume and ratio 
signal intensities across the two channels. These intensities value are taken for the entire 
pixel within the area taken into consideration for the spot (S. Drăghici 2011). 
  
2.6.4.4   SPOT QUALITY ESTIMATION 
Spot quality estimation helps to assess spot in images with questionable values. In 
microarray analysis, the following quality measures are important 
i. Ratio between spot signal area and total spot area  
ii. Shape regularity 
iii. Spot area to perimeter ratio 
iv. Displacement 
v. Spot uniformity (S. Drăghici 2011). 
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Figure 2.3: Microarray image spot and background (Figure adapted from 
M.M. Babu 2004). 
 
 
2.6.5 QUALITY ASSESSMENT 
 Quality assessment is a crucial step after obtaining the raw data in a microarray 
experiment. It involves assessing the quality of data obtained for correct data 
interpretation and to proceed to the next step in the analysis. Since a single error or few 
weird arrays can disrupt the results of the data analysis process, it is mandatory that the 
data be of good quality before proceeding to the next step in the analysis (S. Drăghici 
2011). It thus helps to know whether the whole microarray experiment has worked well so 
that the data used can be considered trustworthy (A. Sánchez and M. C. Ruíz de Villa 2008). 
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Quality assessment starts by visual inspection of the images followed by plots of the raw 
data (N.J. Armstrong and M.A. Van de Wiel 2004). For two channel arrays, quality 
assessment is based on image inspection and plots while for one channel array, it is based 
on image inspection, degradation plots, quality control metrics estimation such as average 
background, present calls, scale factors, hybridization quality etc. (A. Sánchez and M. C. 
Ruíz de Villa 2008). 
 
2.6.6   PREPROCESSING  
Preprocessing is a step in microarray analysis process that extracts meaningful data 
characteristics from dataset obtained from image analysis step (A.L. Tarca et al. 2004). The 
dataset (gene expression dataset) can be represented by a real-valued matrix I where Iij is 
the measured expression level of gene i in experiment (condition) j. The i-th row of the 
matrix represents the expression pattern of gene I and the j-th column represents the 
expression profile of gene j (A. Ben-Dor et al. 1999).  
 
The gene expression matrix can thus be represented as absolute measurement, expression 
ratio (relative measurement), log2 expression ratio, discrete value or vectors i.e. 
representing expression profiles as vectors  (M.M Babu 2004). Since the gene expression 
matrix obtained contains noise, missing values and systemic variation dues to experimental 
procedure, hence it must be preprocessed before any further data analysis (D. Jiang et al. 
2004). Preprocessing can be carried out by background correction, logarithmic 
transformation, and normalization (S. Drăghici 2011, A.L. Tarca et al. 2006). 
 
2.6.6.1   BACKGROUND CORRECTION 
It is the first preprocessing step in microarray analysis (S. Drăghici 2011). It aims to obtain 
an intensity value, which is proportional to the expression level by determining the level of 
hybridization that occurs between the targets and the samples (A. Sánchez, M.C. Ruíz de 
Villa 2004). Background correction can be local, sub-grid, group, blank spots, and control 
spots background correction (S. Drăghici 2011). 
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2.6.6.2   LOGARITHMIC TRANSFORMATION  
Logarithmic transformation is the first technique used to preprocess microarray data. This 
technique provides data that are more meaningful and easy to interpret biologically (S. 
Drăghici 2011). It also makes statistical distribution symmetrical and almost normal, and 
very convenient. Hence, logarithmic transformation is called transformation to normality 
(D.P. Berrar 2003). 
 
2.6.6.3   NORMALIZATION  
Normalization is a step in data preprocessing that aims to correct systemic differences 
(error) between genes or array in a microarray experiment. The systemic error, which may 
be due to variability in sample preparation, experimental bias (A.L. Tarca et al. 2006), 
labeling efficiencies, scanner settings and spatial effect can occur at numerous stages 
during microarray experiment, hence the need for data normalization (S. Dudoit 2002) 
 
The specific normalization techniques to use for data preprocessing depend on the array 
technology used. The Biocondutor projects has various algorithms which includes MAS 5.0, 
Robust Microarray Average (RMA), GC-RMA (for one channel array), and LOESS 
normalization (for two-channel array) which are used for microarray data preprocessing 
(A.L. Tarca 2006). 
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2.6.7   STATISTICAL ANALYSIS 
Once the raw data has been preprocessed, statistical analysis of the data matrix can be 
carried out. In this study, the following analysis will be examined. 
 
2.6.7.1   CLASS DISCOVERY 
Class discovery involves analyzing a set of gene expression profiles with the sole aim of 
discovering subgroups that share similar features. This analysis helps to make meaningful 
biological inference about the set of genes or samples, identify different stages of disease 
severity and identify groups of gene that may behave alike in a disease state (A.L. Tarca et 
al. 2006). Class discovery is also known as clustering analysis (A. Sánchez and M.C. Ruíz de 
Villa 2008) 
 
Clustering is an unsupervised analysis because there is no prior knowledge about the data 
and is currently the most frequently used technique in analyzing gene expression data (S. 
Drăghici 2011). It is the process of grouping objects into different classes called clusters, so 
that objects within a class are more similar to each other while objects from different 
classes are dissimilar (D. Jiang et al. 2004).  
 
To group items (genes or samples) that are similar together successfully, one needs to 
define a good measure of similarity called metrics or distance. There are different 
measures of similarity that can be applied to clustering and this includes Euclidean, 
Manhattan, Chebychev, Correlation, Mahalanobis, Minkowski distances etc. It should be 
noted that the choice of the distance metric to use depends on the array technology in use 
as different array technology represents expression matrix in different format (S. Drăghici 
2011) as explained section 2.1.5.6.  
 
Clustering can be gene-based, sample-based or subspace clustering depending on the 
researchers aims and objectives. In gene-based clustering, genes are the objects, while the 
samples are the features. Gene-based clustering helps to determine co-regulated genes, 
recognize temporary expression patterns and to reduce the prediction model redundancy. 
Sample-based clustering however treats samples as objects and the genes as the features. 
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It helps to identify new tumor classes and to detect experimental artifact. Subspace 
clustering treats both samples and genes uniformly, so that either samples or genes can be 
objects or features and it captures clusters formed by a subset of genes across a subset of 
samples. Clustering results are usually shown in a diagram called dendogram (D. Jiang et al. 
2004). 
 
Clustering algorithms applied to microarray data may be hierarchical or non-hierarchical 
(M.M. Babu 2004) as shown in figure 1.4 below. It should be noted that clustering 
algorithms are dependent on distance metric used and the relationship between patterns 
within the clusters is independent of their position  (S. Drăghici 2011). 
 
 
 
 
Figure 2.4: Clustering classifications (Figure adapted from M.M. Babu 2004). 
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2.6.7.1.1   HIERARCHICAL CLUSTERING ALGORITHM 
Hierarchical clustering algorithm is the oldest clustering algorithm used in the analysis of 
microarray data (S. Drăghici 2011). It creates a hierarchical series of nested clusters (based 
on degree of similarity), which can be represented graphically by a tree like structure, 
called dendrogram (D. Jiang et al. 2004). 
 
Furthermore, hierarchical clustering result may also be shown with a heatmap (A.L. Tarca 
et al. 2006). Heatmap is a color image plot, which is made up of a rectangular array of 
colored block with each block representing the expression level of one gene on the array 
(A. Sánchez and M. C. Ruíz de Villa 2008). Hierarchical clustering algorithm can be 
agglomerative or divisive clustering depending on the method used in drawing the 
dendrogram (D. Jiang et al. 2004).  
 
A. AGGLOMERATIVE CLUSTERING  
Agglomerative clustering is also known as the bottom-up approach. Here each object is 
considered as a cluster and all objects are successfully fused until a single cluster is formed.  
Agglomerative clustering thus lacks robustness and it expensive computationally (S. 
Drăghici 2011). The fusion of all objects (clusters) into a single cluster is based on the 
pairwise distance between them, hence object that are similar are first clustered and the 
process continues until a single cluster is formed. The pairwise distances used in 
agglomerative clustering are single, complete, average linkage and centroid linkage (M.M 
babu 2004). 
 
a.   Single linkage clustering  
This computes the minimum distance between all possible pairs of objects; one from each 
cluster and it chooses clusters that are closest together. This method is insensitive to 
outliers and is also known as minimum distance or nearest neighbor linkage (M.M babu 
2004). The distance here is given as  
 
D (A, B)    =  𝒎𝒊𝒏?⃗? ∈𝑨,?⃗? ∈𝑩 ∥ ?⃗?  - ?⃗?  ∥                    Eqn 1 
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b.   Complete linkage clustering  
It also called maximum distance or farthest neighbor linkage, it chooses the clusters that 
are farthest apart by computing the maximum distance between all possible pairs of 
objects, one from each cluster.  The method major disadvantage is that it is sensitive to 
outliers (M.M babu 2004). Complete linkage distance is given as   
 
D (A, B)    =  𝒎𝒂𝒙?⃗? ∈𝑨,?⃗? ∈𝑩 ∥ ?⃗?  - ?⃗?  ∥                     Eqn 2 
 
c.   Average linkage clustering  
Average linkage clustering evaluates the distance between two clusters as the average of 
the distances between all possible pairs of objects in the two clusters (M.M babu 2004). 
Distance here is given as  
 
D (A, B)    =  𝑨𝒗𝒆𝒓𝒂𝒈𝒆?⃗? ∈𝑨,?⃗? ∈𝑩 ∥ ?⃗?  - ?⃗?  ∥             Eqn 3 
 
d.   Centroid linkage clustering  
It finds the distance between the centers of the cluster. It calculates an average expression 
profile called centroid by first finding the mean in each dimension profile for all objects in 
the cluster and it then measures the distance between the clusters as the average 
expression profile of the two clusters (M.M babu 2004). 
 
B. DIVISIVE CLUSTERING 
Divisive clustering is also known as top-down approach. It is the reverse of agglomerative 
clustering as the entire set of object is seen as a single cluster and split is performed 
repeatedly until a single cluster of each object remains. Divisive clustering is not a popular 
clustering method unlike agglomerative clustering (M.M babu 2004) though it is faster and 
requires less computation (S. Drăghici 2011). 
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2.6.7.1.2   NON-HIERARCHICAL CLUSTERING 
Non-hierarchical clustering algorithm is a partitioning-based clustering algorithm that 
decomposes data into a set of dismembered clusters (D. Jiang et al. 2004). The number of 
clusters is predetermined in this algorithm and the existing objects are grouped into these 
predefined clusters. Non-hierarchical clustering can be K-means clustering, Self-organizing 
maps (SOMs) etc. (M.M babu 2004). Details of k-means and SOMs are explained in the 
subsections below 
 
A. K-means clustering  
K-means clustering is the most wide used non-hierarchical clustering methods. It is simple, 
fast and involves grouping objects arbitrarily into a predetermined number of K clusters (S. 
Drăghici 2011). The predetermined number clusters can be obtained from hierarchical 
clustering results or chosen randomly.  A centroid is then calculated for each cluster and 
objects are re-grouped from one cluster to the other depending on the centroid closer to 
the gene. This procedure of calculating centroid and re-grouping is repeated iteratively 
until the composition of clusters remains unaltered by further iteration (M.M babu 2004). 
 
A shortcoming in K-means clustering is the specification of the number of clusters (K) 
before the algorithm is run. In a situation where there is no fix value for K, user has to try 
different values of K, which is not a good approach (F.M. Al-Akwaa 2012).  
 
B. Self-organizing maps (SOMs)  
SOMs are also known as Self-organizing feature maps or Kohonen map, was developed by 
Tuevo Kohonen in late 80s. It is a clustering method that tends to divide input patterns into 
group of patterns that are similar are plotted next to one another.  SOMs are a grid neural 
network, which can be one (a string), two (an array) or three (a cube) dimensional (S. 
Drăghici 2011). Further details about SOMs and other non-hierarchical clustering 
algorithms can be found in (S. Drăghici 2011). 
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2.6.7.2 CLASS COMPARISON 
Class comparison involves detecting the differences in gene expression levels between 
predefined groups of samples in patients e.g. tumor and normal sample (A.L. Tarca 2006). 
The genes selected are thus called differentially expressed genes while the process is called 
differential expression analysis (A. Sánchez, M.C. Ruíz de Villa 2004).   
 
For a successful class comparison analysis, definite experimental design, hypothesis testing, 
sample size estimation (A.L. Tarca 2006) and performance assessment (S. Drăghici 2011) 
should all be considered.  
 
2.6.7.2.1   HYPOTHESIS TESTING  
Hypothesis testing helps in selecting the real genes that are differentially expressed 
between the groups under study. A null and alternative hypothesis needs to be developed 
with the null hypothesis stating that a given gene on the array is not differentially 
expressed between the two groups under study and the alternative hypothesis stating that 
the expression level of that is different between the two groups. This can be achieved by 
calculating the t-statistic of the expression value of the gene under study measured in the 
two groups. This value will then be compared with a chosen significant value and particular 
threshold (A.L. Tarca 2006). Further details on hypothesis testing can be found in (S. 
Drăghici 2011). 
 
2.6.7.2.2   SAMPLE SIZE  
This refers to the number of measurements in an experiment. Its computation required 
knowledge about the minimum fold change to be detected, gene expression variances 
within each group and statistical power. Large number of samples results in high fold 
change value, more expression variability and high statistical power, which will in turn give 
more differentially expressed genes, hence a large sample size is encouraged. However due 
to the high cost of microarray experiment, a certain number of replicate such as 5 samples 
per group are usually adopted (A.L. Tarca 2006). 
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2.6.7.2.3   PERFORMANCE ASSESSMENT  
Performance assessment of each gene selection method helps to determine the best 
approach since there are several approaches used in selecting genes that are differentially 
expressed (DE Genes). Gene selection methods performance can be computed in terms of 
accuracy, specificity, sensitivity, positive predicted value (PPV), and negative predicted 
value (NPV). These measures have values between 0 and 1 and are sometimes expressed in 
percentage (S. Drăghici 2011). They are defined as follows  
 
Accuracy = (T.P + T.N)/ (T.P + F.P + T.N + F.N)         Eqn. 4 
 
                  Specificity = T.N / (T.N + F.P)                                       Eqn. 5 
 
                               Sensitivity = T.P / (T.P + F.N)                                       Eqn. 6 
 
                               PPV = T.P / (T.P + F.P)                                                    Eqn. 7 
 
                               NPV = T.N / (T.N + F.N)                                                  Eqn. 8 
 
Furthermore, they all play a major role in selecting the best approach for selecting genes 
that are differentially expressed and they all depends on prevalence, which is given as  
 
                               Prevalence = (T.P + F.N) / (T.P + F.P + T.N + F.N)       Eqn. 9 
 
Using change/unchanged as the condition, the following definitions hold: T.P (True 
positives) are the true change that are reported as change, F.P (False positives) are 
unchanged reported as change, F.N (False negatives) truly change reported as unchanged, 
and T.N (True negatives) are the truly unchanged that are reported. A perfect gene 
selection approach will produce value of 1 for accuracy, specificity, sensitivity, positive 
predicted value (PPV), and negative predicted value (NPV) (S. Drăghici 2011). 
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2.6.7.2.4 METHODS OF SELECTING DIFFERENTIALLY EXPRESSED GENES  
Several methods of selecting differentially expressed genes have been developed but the 
methods employed in this study will be discussed briefly. 
 
A. Fold change method 
The fold change approach is the simplest and the most natural method used in finding 
genes that are differentially expressed between the two conditions (reference and 
experiment). An easy way to achieve this is by calculating the ratio between the two 
expression levels for each gene (S. Drăghici 2011). This ratio is then log-transformed (log2) 
and the transformation helps to improve the symmetry of the data distribution by giving a 
mean log-ratio of zero (A.L. Tarca et al. 2006). 
 
To select the genes that are differentially expressed, a histogram which horizontal axis 
represents the log-ratio can be plotted. A threshold will then be set and the differentially 
expressed genes (DEG’s) are those outside this threshold. This method’s major drawback is 
that the fold threshold is chosen arbitrarily, which might be inappropriate and it doesn’t 
consider the variance of the expression value measured (S. Drăghici 2011). 
 
B. Unusual ratio method 
This method involves the selection of genes for which experiment and reference values 
ratio is a certain distance (±2 multiplied by standard deviation) from the mean 
experiment/control ratio.  This can be achieved by applying a z-transform to the log ratio 
value. The z-transform thus subtracts the mean and divides by the standard deviation. This 
method is also simple, intuitive and more superior than the fold change method as it adjust 
the cut-off threshold automatically, hence it picks the most affected genes irrespective of 
the number and extent the genes regulated.  However, this method report 5% of the genes 
as differentially regulated even if there is none and 5% of the genes even if there are more 
differentially regulated genes (S. Drăghici 2011). 
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C. T-Test Method  
This method employs classical hypothesis testing methodology along with some correction 
for multiple comparison (Bonferroni, Benjamini-Horcberg etc.) in selecting genes that are 
differentially expressed (S. Drăghici 2011). 
 
Classical hypothesis testing (statistical hypothesis) refers to the assumption made about 
the genes involved the microarray experiment in other to make statistical decision about 
those genes on the basis of sample information. These assumptions are statements about 
genes probability distributions. The major steps in hypothesis testing are as follows 
 
a. Define the problem clearly 
b. Generate null and alternative hypothesis. 
Null hypothesis is the hypothesis that occurs by chance while an alternative 
hypothesis is that hypothesis that differs from the given null hypothesis. 
c. Choose level of significance (S). 
   Level of significance refers to the probability of rejecting a true null hypothesis. 
d. Calculate statistics based on data and compute p-value.  
  P-value is defined as the probability of drawing the wrong deduction by rejecting a   
  null hypothesis that is true. 
e. Compare p-value and significant level in other to accept or reject null hypothesis. 
   If p-value is less S, we reject a true null hypothesis (Type I error) otherwise, we  
   accept false null hypothesis (Type II error) (S. Drăghici 2011, M.R. Spiegel et al. 2001). 
 
This method is conservative and it assumes that genes in the experiment are independent 
which is not always true in any real data set (S. Drăghici 2011).  
 
In the past, many publications of microarray experiment determine differentially expressed 
genes solely from fold-change analysis by using a 2-fold cutoff. This method however does 
not consider variability in the data; hence its results are not reliable. T-test or the Wilcoxon 
test approach is later introduced in order to correct the defects in fold change analysis but 
it was found out that the result obtained with this test produces a lot False Discovery Rates 
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(FDRs) in small number of samples. In addition, the result obtained is poorly related to that 
obtained from the fold change analysis (D.J. McCarthy and G.K. Smyth 2009).   
 
In recent years, modern statistical tests for microarray analysis have been developed. 
These tests derive their information between genes adopting empirical Bayes along side 
other statistical methods. In addition, the tests have thus performed better than the t-test 
and give results that are related with fold change analysis.  Since these modern statistical 
tests allows genes with small fold change to be considered significant statically. Hence, it is 
now common practice that differentially expressed genes satisfy at the same time both p-
value and fold-change thresholds. Peart et al. (2005) and Raouf et al. (2008) obtained 
differentially expressed genes by setting a fold-change cutoff of at least 1.5 and a p-value 
less than 0.05 after performing multiple testing. In addition, Huggins et al. (2008) adopts a 
fold change of 1.3 and a p-value less than 0.2 to find differentially expressed genes. It was 
observed that the combination of fold change and p-value threshold gives differentially 
expressed genes that are more meaningfully biologically than using the p-value alone (D.J. 
McCarthy and G.K. Smyth 2009).   
 
Other methods used for selecting differentially expressed genes are Analysis Of VAriance 
(ANOVA), Noise sampling, Model-based maximum likelihood estimation, Significance 
Analysis of Microarray (SAM), moderated t-statistics, Use of Biocondutor packages such as 
Limma (S. Drăghici 2011), DESeq, DESeq2 etc.  
 
 
 
 
 
 
 
 
 
  38 
2.6.7.3 CLASS PREDICTION 
Class prediction analysis involves discovering class membership of a sample based on its 
gene expression profile. Its main goal is to accurately predict the class membership (e.g. 
phenotype) of a new individual by building a classifier that can distinguish between the 
classes. This goal can be achieved by first learning the existing complex relationship 
between the class membership and the expression values of the genes (A.L. Tarca et al 
2006). Class prediction analysis involves three major components namely: 
 
A.  FEATURE SELECTION 
Feature selection is the first component of class prediction analysis and it defines the 
number of genes to include in the predictor to be built. Feature selection is of great 
importance in microarray studies due to the fact that the number of informative variables 
used for differentiating our classes of interest is usually very small when compared to the 
overall genes on the microarray. Hence it is of great importance to choose informative 
genes to be use by the class predictor (R. Simon 2003).  
 
Furthermore, future selection employs class comparism analysis, as it’s most common 
approach i.e. selecting and identifying differentially expressed genes among gene classes 
when the classes are treated one after the other (R. Simon 2003). 
 
B. SELECTING PREDICTOR FUNCTION (CLASSIFIER) 
Classifiers are functions that take as input the values of several features (variables that are 
independent) from an example set of independent variable values and presume the 
category that the example set belongs i.e. a classifier is a function that produce a class label 
prediction from an example input. Classifiers are usually trained so as to learn some useful 
parameters from the training data and this turns the classifier to a model that reveals the 
relationship between variables and the training set class labels. The relationship between 
the variables and class labels in the training set are tested using the test data (F. Pereiraa et 
al. 2009). 
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Defining a predictor function that will for any expression vector gives a class label is the 
second component of class prediction analysis. Predictor function can be nearest neighbor 
predictor, linear discriminant analysis, logistic regression, support vector machine etc. (R. 
Simon 2003). 
 
The K nearest neighbor classifier, also called case based reasoning, example based 
reasoning, memory based reasoning, instance based learning and lazy learning is a classifier 
that categorize samples based on the similarity measure of the class of their nearest 
neighbor. It is a very popular, easy to understand, effective and very efficient algorithm 
used in classification, statistical estimation and pattern recognition (M.A. Jabbar et al. 
2013).  
 
Furthermore, KNN is not expensive computationally and hence it is useful for data that 
changes quickly. KNN algorithm starts by first measuring the distance of a new sample with 
all the samples in the training set. The calculated euclidean distance are arranged in 
ascending order and the K sample, which distance is closest to the new sample are called 
the k-nearest neighbors. The K-nearest neighbors obtained are then used to categorize the 
new sample to the predefined class and this depends on the type of data in use. If data 
contain categorical variables, then a voting (simple or weighted) is adopted. However, for 
data continuous or quantitative variables, mean, geometric mean or median is adopted (Z. 
Jan et al. 2008). 
 
The K value selected for KNN algorithm is important in evaluating the model effectiveness 
as this helps to decide the best way to use the available data so as to generalize KNN 
algorithm. If the value of k is large, then the variance value is reduced as a result of noisy 
data.  However, this large value of k is disadvantageous since it causes bias. The bias thus 
makes the learner to ignore pattern, which might have useful insights. The value of k is 
usually taken as the square root of the number of observation in the data (Analytics 
Community 2016).  
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C. CLASSIFIER PERFORMANCE ASSESSMENT 
The final component of class prediction analysis involves assessing the performance of the 
built classifier for future samples. This is carried out by determining how well the classifier 
predicts unseen sample and reliability of the prediction. Accuracy of class predictor can be 
estimated with split-sample and cross-validation method (R. Simon 2003). 
 
The split-sample method is the most straightforward method of estimating the accuracy of 
future prediction of samples. It involves splitting the current set of data into training and 
test set with the test set emulating the future samples, which class label is to predicted.  
It should be noted that samples within the test set shouldn’t be used for developing the 
prediction model and choosing the genes to be used in the model building (R. Simon 2003). 
 
Cross-validation method on the other hand also involves splitting data into training and 
test set. The test set in this case consist of a single sample, which is placed aside and not 
used in class prediction model development, while the training set is used for selecting 
informative genes and model parameter are adapted to the data. (R. Simon 2003). 
 
Cross-validation can be leave-one-out cross-validation, k-fold cross validation, hold-out set 
and bootstrapping. Details of different cross-validation techniques can be found in (J.H. 
Friedman et al. 2001). 
 
The assessment result of the built classifier is usually displayed on a confusion matrix. A 
confusion matrix refers to a table that classify foresighted and actual elements according to 
how they match with the foresighted elements vertical and the original elements shown 
horizontally or vice-versa. A confusion matrix can be two by two; three by three etc. 
depended on the numbers of classes available in the built model as shown in the figure 
below (B. Lantz 2015). From the table, performance is measure by accuracy and error rate 
and other parameters as described in section 2.6.7.2.3.  
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FORESIGHTED VALUE 
                                                         Negative               Positive 
 
                             Negative 
 
     ORIGINAL  
        VALUE 
                            Positive  
 
Table 2.1: A two by two confusion matrix 
 
2.6.8   BIOLOGICAL VERIFICATION AND INTERPRETATION  
The result of microarray analysis irrespective of the platform and the analysis method 
employed is, in most cases the list of differentially expressed genes. This list of 
differentially expressed genes needs to be transformed to the underlying biological 
phenomena for better understanding. To achieve this, the list needs to be to be translated 
into functional profile, which will give insight into the cellular mechanism relevant in the 
condition under study. Many tools have been developed to help with this task among 
which are Gene Ontology (GO), Onto-Express, DAVID etc. The ontology tools are thus 
similar in their approaches but are greatly different in many respects, which influence the 
nature of the results of the analysis  (P. Khatri, and S. Drăghici 2001). Details of different 
ontology tools, their capabilities, statistical model and annotation databases are explained 
in (P. Khatri, and S. Drăghici 2001). The interpretation of the list of differentially expressed 
genes can be analyzed with a method called enrichment analysis.  
 
 
 
 
 
 
T.N 
True Negative 
 
F.P 
False Positive 
 
F.N 
False Negative 
 
T.P 
True Positive 
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2.6.8.1 ENRICHMENT ANALYSIS 
Enrichment analysis is defined as the method of obtaining biological significance in term of 
statistical significance and its main objective is to interpret gene group in order to identify 
biological information for the event under study. Gene Ontology (GO) database is very 
efficient in performing enrichment analysis (M. Mayo and J. Luís 2014). This analysis thus 
helps to interpret the results obtained from the statistical analysis of microarray data in 
other to get biological meaning into the data under study.  
 
2.6.8.2 METHODS USED IN ENRICHMENT ANALYSIS 
Several methods have been developed in the past with the aim of seeking biological 
meaning based on enrichment analysis. All the methods are similar and they work in two 
steps. First, they consider list of genes of interest from a gene population, which results 
from an experiment and maps each gene in the list to the annotation terms that are 
correlated with it. Second, enrichment of each gene annotated in each category is 
computed. Comparing the proportion of genes of interest assigned to such category 
against the genes from the population that were in that same category does the 
computation. Methods in enrichment analysis are Singular Enrichment Analysis, Modular 
Enrichment analysis and Gene Set Enrichment analysis (M. Mayo and J. Luís 2014). Details 
of each method are explained the subsections below. 
 
2.6.8.2.1 SINGULAR ENRICHMENT ANALYSIS 
Singular Enrichment Analysis (SEA) takes a list of genes that are differentially expressed 
from obtained from class comparison analysis by performing a statistical test and then uses 
the list to query different annotation terms one after the other.  A threshold of significance 
is set; terms with p-values lower than this threshold is ordered by the enrichment p-value. 
Binomial probability, Hypergeometric distribution, Fisher’s Exact Test, or Chi-square is the 
common statistical method used for SEA (M. Mayo and J. Luís 2014). 
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2.6.8.2.2 MODULAR ENRICHMENT ANALYSIS 
Modular Enrichment Analysis (MEA) is an analysis that uses list of differentially expressed 
genes to test multiple annotation term at once considering the relationship between each 
pair of terms. Since MEA considers the relationship between each pair of term, it is 
possible to obtain unique biological meaning, which cannot be shown by a single 
annotation term (M. Mayo and J. Luís 2014). 
 
2.6.8.2.3 GENE SET ENRICHMENT ANALYSIS 
Gene Set Enrichment Analysis (GSEA) is a method used to find out whether a gene set 
display statistical significant difference between phenotypes by considering the measured 
difference that exist between them for individual genes from high-throughput experiment. 
It takes in a list of differentially expressed genes and a set of gene expression values 
measured from the two phenotypes under study. GSEA depends on thousands of 
predefined gene sets assembled from GO, KEGG etc. (M. Mayo and J. Luís 2014). 
 
Furthermore, GSEA’s statistical method involves testing some gene set from the high-
throughput experiment for enrichment by arranging all the genes in the entire list based on 
the correlation of the gene expression pattern with the phenotype. The arrangement thus 
gives the fraction of genes that appear in the gene set called hits and the fraction of genes 
that doesn’t appear in the gene set called misses, at a particular position in the entire list of 
genes. The result here is then used to compute enrichment score with Kolmogorov-
Smirnov statistic, z-score or t-test (M. Mayo and J. Luís 2014). 
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2.6.8.3 GENE LIST ANALYSIS WITH PANTHER  
Gene list analysis can be achieved with PANTHER ((Protein Analysis THrough Evolutionary 
Relationships). PANTHER is a commonly used online tool employed for evolutionary and 
efficient classification of protein and analysis of biological data on a large scale. It makes 
use of data set from UniProt Reference Proteomes, which are arranged into families of 
similar genes. Results from PANTHER is shown on a phylogenetic tree, which is built for 
each family reveals the evolutionary relationship between all the genes in the family and 
also transcription, speciation, gene duplication and horizontal transfer processes. 
Phylogenetic tree from PANTHER thus deduce all the processes above for all the available 
protein coding genes in organisms and helps to determine groups of genes that are similar 
within each gene family (H. Mi et al. 2016).  
 
Furthermore, PANTHER gathers proteins, which have been further divided into families 
that are functionally related using human knowledge. Accurate association with function 
such as ontology terms and pathways is possible because the subfamilies of proteins in 
PANTHER model these functions divergence within the families of protein (H. Mi et al. 
2005). In addition, PANTHER helps to translate protein sequence relationship to functional 
relationship in an perfect and flexible way. It is made up two main parts namely; PANTHER 
library and PANTHER index. PANTHER library refers to different books, with each book 
serving as a protein family in terms of a Hidden Markov Model (HMM), multiple sequence 
alignment, and a family tree while PANTHER index and it thus depicts compressed ontology 
and it performs the function of shortening and maneuvering molecular functions and 
biological processes associated with the protein families and their subfamilies (P.D. Thomas 
et al. 2003).  
 
 
 
 
 
 
  45 
2.7 OVERVIEW OF SURVIVAL ANALYSIS  
Survival analysis also known as failure analysis, event history analysis, hazard analysis, 
duration analysis, or transition analysis is an analysis developed by biostatisticians to 
predict the occurrence of death. It deals with gathering different statistical methods, which 
are used to interpret an event, its occurrence and timing. The event to be interpreted can 
be deaths, births, marriages, divorces, job terminations, migrations etc. (P.D. Allison 2012).  
The occurrence of an event of interest say death is described with the term “failure”, which 
in some cases might represent a successful event e.g. therapy recovery. The amount of 
time it take for an event of interest to occur is referred to as the survival time (M. 
Stevenson 2009). 
 
Furthermore survival analysis deals with analyzing survival time data, which can be 
obtained by different approaches. The approaches used in obtaining the survival time data 
thus affect its analysis. The following sampling (data collection) processes are used in 
generating survival time data (S.P. Jenkins 2005). 
 
a. Stock Sampling Approach 
Standard sampling approach is an approach, which involves the random sampling of 
individuals that are in a particular state of interest (e.g. Tumor relapse). Not all 
individuals in this state are interviewed and the time at which they entered the state of  
interest is determined (S.P. Jenkins 2005). 
 
b. Inflow Sampling Approach 
This approach involves random sampling of all individuals that are in a defined state of 
interest and each of the individual in the study are followed until a predefined date or end 
of the study (S.P. Jenkins 2005). 
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c. Outflow Sampling Approach 
This approach generates survival data by taking random sample of individuals that leaves 
state of interest. In this approach, the start date of the state of interest is determined (S.P. 
Jenkins 2005). 
 
d. Population Sampling Approach 
This approach involves the overall sampling of the entire population. Sampling in this  
approach is not related to the state of interest. In this approach, individuals are asked  
about their current and past state [(S.P. Jenkins 2005).  
 
It should be noted that a survival data can be generated by the combination of any or all of 
the sampling method stated above depending on purpose the data is meant for (S.P. 
Jenkins 2005). 
 
2.7.1 CONCEPTS IN SURVIVAL ANALYSIS 
In analyzing survival data, it is important to explain the following concepts 
 
2.7.1.1 EVENT  
Events refers to a change that takes place at a particular point in time, hence it is 
dependent on time. Examples of events are deaths, marriages, promotions etc. In 
understanding survival analysis, it is quite important to note that: firstly, the event to be 
modeled must be properly defined before proceeding with the analysis of data (P.D. Allison 
2012). 
 
Secondly, one must decide whether to treat all events as the same or to distinguish them. 
The distinctions between different events types depend on the available data, provided it 
gives enough information for the distinction. Distinguishing events helps to reveal the 
different effects that predictor variables used in our model has on different event types 
(P.D. Allison 2012). 
  47 
Thirdly, when each individual have the different repeated events associated with them, 
one must decide whether to pick the first event or to employ a technique that merge all 
the events together (P.D. Allison 2012). 
 
2.7.1.2 TIME TO EVENT  
Time to event or survival time is the amount of time it takes for an event to take place. It is 
usually given in days, weeks, months, years etc. and the following terms helps in describing 
survival time. 
 
A.  Instantaneous Failure Rate 
If the count of the length of time taken for an event to occur is plotted as a function of  
time on a frequency histogram, a curve fitted to this histogram gives the instantaneous   
failure rate of the event in question. It is denoted by f(t) and is shown in figure 1.6  
below. Failure function F(t) signifies the fraction of individual who have died as a  
function of time t and it is obtained by setting the area under curve of fig 1.6 to be equal    
to 1. Then it is observed that for any time t, the area under the curve to the left of time t  
represents the failure function. Hence individual in this portion have experienced the  
event of interest (death) (M. Stevenson 2009). 
 
B. Survival Function 
Survival function is denoted by S(t) and is defined as the fraction of individual in a   
population who have survived to time t. It is denoted by the area under the instantaneous 
failure curve to the right of time as shown in figure 1.6 and it gives a survival curve when 
plotted against time t (M. Stevenson 2009). It is given as  
 
S(t) = Probability (an individual survives longer than t)         Eqn   12(a) 
 
                                                 S(t) = P(T > t)                                                      Eqn   12(b) 
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Since the area to the left of the curve in figure 1.6 represents the failure function F(t),  
then, S(t) can also be given as   
       
S(t) = 1-Probability (an individual fails before t)                       Eqn   13(a) 
 
                                                 S(t) = 1 - F(t)                                                        Eqn   13(b) 
 
 
 
 
Figure 2.5: Line plot of instantaneous failure rate. Figure adapted from (M. Stevenson 
2009). 
 
C. Hazard Function 
Hazard function h(t) is defined as the instantaneous time at which an individual that is  
selected randomly are alive at time (t -1) dies at time t. (E.T. Lee and J.W. Wang 2003). 
Also known as the conditional failure rate, instantaneous failure rate, conditional mortality 
rate, or force of mortality, gives the failure probability during a small interval provided the 
individual has survived to the start of the interval (M. Stevenson 2009). 
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2.7.1.3 PERIOD OF OBSERVATION 
The period of observation in survival analysis refers to the process of observing each 
individual in the study over an interval of time. The time is thus recorded provided an event 
occurred, otherwise the observation continues and observation is stopped when an 
occurred event doesn’t repeat itself.  For a proper and accurate analysis of survival data, 
the origin and termination time results should be accounted for and validated (P.D. Allison 
2012). 
 
2.7.1.4 CENSORING AND TRUNCATION IN SURVIVAL ANALYSIS 
2.7.1.4.1 CENSORING 
An event is said to censored if it doesn’t occur during the period of observing an individual 
but the total time in which the event doesn’t occur is known. Individuals in this category 
are called censored observation and the data contributed by censored observations are 
included in the study until they are excluded from the risk set (M. Stevenson 2009). 
 
However, an event of interest is said to be exact or uncensored if it occurs during the 
period of observing an individual and the number of days from the start to the end of event 
is known (E.T. Lee and J.W. Wang 2003). Censoring can be divided into the following  
 
A. RIGHT CENSORING 
In right censoring, an event of interest usually occurs after the recorded follow-up period 
(M. Stevenson 2009). This means that an observation is ended before an individual 
experiences an event of interest. It is the most conventional type of censoring (P.D. Allison 
2012) and it can be sub-divided into the following (E.T. Lee and J.W. Wang 2003). 
 
a. Type I Censoring  
In type I censoring, all censored observation corresponds to the length of the study period 
provided there are no accidental losses such as death (E.T. Lee and J.W. Wang 2003). 
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b. Type II Censoring  
In type Ii censoring, all censored observation corresponds to the length of the largest  
uncensored observation provided there are no accidental losses such as death.  Type I  
and type II censored observations are also known as singly censored data since the study  
period here is not fixed and individuals in this study starts at the same time (E.T. Lee and    
J.W. Wang 2003). 
 
c. Type III Censoring  
Here, the study period is fixed and individual can enter the study at different time. It is also 
called progressively censored data with different censored times (E.T. Lee and J.W. Wang 
2003). 
 
In solving right censoring problems, it is best to assume that the censoring doesn’t give 
enough information. For the assumption above to hold, the censoring time of the entire 
individual in the study must be the same. However, it should be noted that an informative 
censoring is one in which its censoring time occurs at varying time due to individuals 
leaving the study at different time (P.D. Allison 2012). 
 
B. LEFT CENSORING 
In left censoring, an event of interest usually occurs before the recorded follow-up period 
(M. Stevenson 2009). It is the least common among censoring types and the exact time 
before the event of interest occur is unknown (P.D. Allison 2012). 
 
C. INTERVAL CENSORING 
In interval censoring, an event of interest usually occurs between two times, but the exact 
time is unknown. It means that one can know that an event occurs between date A and B 
but there is no clear knowledge abut the date (M. Stevenson 2009).  
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2.7.1.4.2 TRUNCATION 
Truncation on the contrary means that the outcome of an event of interest cannot 
probably occur. Truncation is divided into two namely:  
 
A. RIGHT TRUNCATION 
Right truncation occurs when an individual leaves a study after the study has commenced 
and progressed to a particular stage. Hence, individuals here cannot experience the event 
of interest at the time he left the study (M. Stevenson 2009). 
 
B. LEFT TRUNCATION 
Left truncation on the contrary occurs when an individual enters a study after the follow-up 
period has commenced. Hence, individuals cannot experience the event of interest at the 
time they enter the study because the follow-up period has already started (M. Stevenson 
2009). 
 
2.7.2 DESCRIBING SURVIVAL DATA 
Once the survival data has been collected, the next step is to describe it graphically with a 
survival curve. The plot of this curve helps to reveal the patterns in the survival data, 
determine data distribution. Data pattern and its distribution are thus important in 
describing survival data. Methods used in describing data can be non-parametric or 
parametric (M. Stevenson 2009). 
 
2.7.2.1 NON-PARAMETRIC METHOD 
Non-parametric methods of describing survival data are quite simple to understand and 
implement. They are effective than parametric method when there are no known 
theoretical distributions and less effective when the time to event follow a theoretical 
distribution. Hence, it is encourage analyzing survival data with non-parametric methods 
before attempting to fit a theoretical distribution. These methods thus give estimates and 
graphs that help in selecting a distribution if we are to find a model for the data at hand 
(E.T. Lee and J.W. Wang 2003). 
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Non-parametric method is a method that is used when there is no theoretical distribution 
that fits the survival data. This method is also known as semi-parametric or and is usually 
used in epidemiology. The popular non-parametric methods used in describing survival 
data are Kaplan-Mier method and the life-table method (M. Stevenson 2009). 
 
A. KAPLAN-MIER METHOD 
Kaplan-Mier method is a method developed Kaplan and Mier in the year 1958, also called 
product-limit method and is based on the survival times of an individual. It estimates 
survival function, probabilities and graphical representation of survival distribution. It is the 
most wide used non-parametric method of analyzing survival data and is applicable to 
small, medium and large samples (E.T. Lee and J.W. Wang 2003). The characteristics of 
Kaplan-Mier method are as follows 
 
a. It assumes that censoring times are not dependent on survival time i.e. a censored 
observation is independent of the state of interest (E.T. Lee and J.W. Wang 2003). 
 
b. The survival curve produced by this method gives the median survival time when S(t) = 
0.5 at time t. If there are times t1 and t2 when at S(t) = 0.5, then the median survival 
time equals any t value between t1 and t2 (E.T. Lee and J.W. Wang 2003). 
 
c. Median survival time from this method is unavailable if number of censored 
observation exceeds the number of uncensored observation (E.T. Lee and J.W. Wang 
2003). 
 
d. It is based on individual survival times; hence it is less prone to bias (M. Stevenson 
2009). 
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Kaplan-Mier estimator of survival at time t is given as  
 
S(t) = ∏
(𝒎𝒌− 𝒅𝒌)
𝒎𝒌
𝒌:𝒕𝒌≤𝒕                               Eqn 14 
 
Where tk, k = 1, 2, .., n is the total set of failure times, dk is the number of failures at time tk, 
mk is the number of individuals at risk at time tk and 𝒎𝒌 − 𝒅𝒌  is the number of individual 
in the sample who will survive longer than tk (M. Stevenson 2009). 
 
B. LIFE-TABLE METHOD 
It is one of the ancient methods employed for measuring death and interpreting 
populations’ survival experience. Actuaries, demographers, governmental agencies, and 
medical researchers have made use of the life-table to study survival, population growth, 
fertility, migration, length of married life, and length of working life etc. Clinical life-tables 
are developed by epidemiologist to investigate patients with a particular disease who have 
been followed for a period of time in a study. Other examples of life-table are population 
life-table and survival life-table (E.T. Lee and J.W. Wang 2003). The life-table method 
assumes that   
 
a. There are random selections of individual throughout each interval. This assumption 
leads to bias when intervals are long, however with short intervals, there is no bias (M. 
Stevenson 2009). 
 
b. Failure rate within an interval is equal for all individuals and doesn’t dependent on the 
probability of survival at other time periods (M. Stevenson 2009). 
 
Furthermore, the life-table method is similar to Kaplan-Mier method but its survival times 
are grouped into intervals and thus efficient for large data sets (E.T. Lee and J.W. Wang 
2003). 
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2.7.2.2 PARAMETRIC METHOD 
Parametric methods are employed in describing survival data when the distribution of the 
survival function follows predictable pattern. This method is sometimes preferred to non-
parametric method because it evaluates survival time easily even after the occurrence of 
the event of interest (M. Stevenson 2009). Parametric methods used to describe survival 
time are exponential, Weibull, Gompertz, lognormal, log-logistic, and gamma (P.D. Allison 
2012). 
 
2.7.3 COMPARING SURVIVAL CURVE 
It is a usual practice to compare the survival between two or more groups. For instance one 
may compare if it takes a longer time for a particular disease to develop in a one region of 
a country compered with another region, if a treated patient survive longer than expected 
etc. The survival curve gives an insight on how the time to event differs among the groups 
under study. In addition, different survival curves for different group helps to recognize the 
factors that play important role in deciding survival. The curve thus serves as a tool for 
effective screening these important factors, which influence can then be tested with 
multivariate analysis after they are screened  (M. Stevenson 2009). The comparism of 
survival curve for uncensored observation can be done with non-parametric test. The non-
parametric tests are Gehan’s generalized Wilcoxon test, the Cox-Mantel test, the log-rank 
test, Peto and Peto’s generalized Wilcoxon test and Cox’s F-test (E.T. Lee and J.W. Wang 
2003). 
 
The log-rank test, which is also called the Mantel log-rank test, the Cox Mantel log-rank 
test, and the Mantel- Haenszel test, appears to be the most popular test employed in 
comparing survival curves. It finds application in data with continuous censoring and it 
assigns identical weight to failure that occur early and that that occur lately. Log-rank test 
works with the assumption that hazard functions are parallel for the two groups. With this 
assumption, it picks each time point when a failure event takes place and creates a two by 
two table, which contains as columns the number of deaths and the overall number of 
subjects that are under follow up.  The observed death, expected death and the variance of 
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the expected number are calculated and summed over all table to yield a chi-square 
statistics having a degree of freedom of 1 (E.T. Lee and J.W. Wang 2003). 
 
Furthermore, for each group, the log-rank test also calculates the ratio of observed and 
expected number of death. This values thus relates the number of death observed to the 
expected number during follow up with a null hypothesis that he survival curve for the 
separate groups is the same as that for the combined data (E.T. Lee and J.W. Wang 2003). 
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3. AIMS OF THE STUDY 
The aims of this study are as follows 
 Download Glioblastoma Multiforme (GBM) preprocessed data matrix from 
microarray platform 
 Classify genes and samples into subgroups (clusters) with similar features from a set 
of gene expression profile 
 Identify differentially expressed genes among predefined phenotypic group of 
samples 
 Discover class membership of samples from patients based on their gene 
expression profile 
 Interpret differentially expressed genes with PANTHER for pathway and functional 
enrichment analysis 
 Analyze GBM cluster aggressiveness by performing survival analysis on GBM’s 
clinical data  
 Verify pathways and functional enrichment analysis result obtained from 
differentially expressed genes with independent glioblastoma dataset 
 
 
 
 
 
 
 
 
 
 
  57 
4. MATERIALS AND METHODS 
4.1 SOURCE OF DATA 
4.1.1 EXPERIMENTAL DATA 
The data was obtained from The Cancer Genome Atlas (TCGA) via the University of 
Califonia Santa Cruz (UCSC) Cancer Browser as a zipped file named 
“TCGA_GBM_exp_u133a-2015-02-24.tgz”. This means that the GBM gene expression data 
is obtained from microarray experiment (Affymetrix HT Human Genome U133a). The 
unzipped file thus contains a preprocessed data matrix, clinical and other relevant 
information used in this study. The preprocessed data matrix has 12042 rows (genes) and 
539 columns (samples) i.e. there are 12042 genes and 539 tumor samples all from patients 
with GBM. The clinical data has 147 columns, which contains clinical information of GBM 
patients. 
 
The National Cancer Institute (NCI) and National Human Genome Research Institute 
(NHGRI) collaborated to create TCGA, which has helped to create global and complex maps 
of the main genomic changes in different types of cancer. Its datasets are available publicly 
and have been employed in different types of research playing different roles in over one 
thousand studies of cancer by independent researchers and in the publications from the 
TCGA research network (The Cancer Genome Atlas 2016). 
 
Furthermore, TCGA has developed a genomic data analysis pipeline, which on a large scale 
can accurately assemble, pick, and evaluate tissues from human for genomic alterations. 
The success enjoyed by the TCGA project louds the effect of teamwork in science and it can 
be used as a prototype for future project. The Center for Cancer Genomics (CCG) is an NCI 
initiative that will replace the TCGA in 2017 and it will rely on the success enjoyed by TCGA 
by making genomic data available publicly using similar model collaboration for extensive 
genomic analysis (The Cancer Genome Atlas 2016). 
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In addition, the cancer browser by the University of Califonia Santa Cruz (UCSC) offers a 
series of web-based tools used to visualize, harmonize and examine cancer genomics data 
and its corresponding clinical data.  The UCSC Cancer Browser is developed and maintained 
by the collaborative effort of the UCSC Cancer Genomics and UCSC Genome Browser 
groups. Both groups operate in the Center for Biomolecular Science and Engineering (CBSE) 
located at the University of California Santa Cruz (University of California Santa Cruz 
Genome Browser 2016). 
 
4.1.2 VALIDATION DATA 
The GBM dataset employed for result validation is obtained from the Gene Expression 
Omnibus (GEO) database via the National Center for Biotechnology Information (NCBI) 
website as a zipped file named “GSE20736_RAW”. The unzipped file contains the raw CEL 
files, which are used in this study for validation.  
 
GEO is a global archive, available to the general public. . GEO stores and distributes freely, 
next-generation sequencing, microarray, and different high-throughput functional genomic 
data, obtained from various research communities. Its main goals are to provide a 
database that is flexible, functional, and can efficiently store high-throughput functional 
genomic data. In addition, the archive provides a database that allows users to examine, 
detect, inspect and download datasets from experiments of their interest; and beyond it 
offers easy submission methods as well as schemes that back complete and well annotated 
data deposits (National Center for Biotechnology Information 2016) 
 
4.2 MATERIALS USED IN DATA ANALYSIS 
The major tool used in the analysis of the data obtained form The Cancer Genome Atlas 
(TCGA) is R and packages from Biocondutor.  
 
The programming language R is a GNU project with an environment developed by John 
Chambers and colleagues at the Bells laboratories (Lucent Technologies). The programming 
language is used for analytical computing and graphical visualization.  It is a highly flexible 
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programming language, which can perform series of statistical analysis such as nonlinear 
and linear modeling, standard statistical tests, time-series analysis, classification, class 
discovery, regression analysis, and graphical techniques (R Project for Statistical Computing 
2016). 
 
Furthermore, R gives a standard graphical plots when used for graphical display and it also 
has in built mathematical symbols and formulae. It is available as free software and runs on 
t UNIX platforms, FreeBSD, Linux, Windows and MacOS. The R environment includes 
efficient data manipulation and storage facilities, collection of standard tools for data 
analysis and graphical visualization, and operators for matrices manipulation (R Project for 
Statistical Computing 2016). 
 
On the other hand, Bioconductor is an open development software project, which is 
available freely online. It offers the tools for extensive analysis of high throughput genomic 
data using R programming language. In addition, it contains many metadata packages, 
which provides pathway, organism, microarray and other annotations.  Bioconductor has 
both development and release versions with the later updated two time in a year and 
relevant for most users and the former has new features and packages, which are added 
before the incorporation of the release version (Bioconductor 2016). 
 
Furthermore, Bioconductor project aims to give public access to many efficient statistical 
and graphical techniques for genomic data analysis, enable the addition of biological 
metadata in genomic data analysis, produce excellent documentation and reproducible 
research for improve scientific findings and train researchers on computational and 
statistical techniques employed in genomic data analysis etc. (Bioconductor 2016). 
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4.3 CLASS DISCOVERY ANALYSIS 
This analysis aims to find subgroup of genes and samples that are identical. Both 
hierarchical clustering and non-hierarchical clustering was performed on the gene 
expression data matrix. Since there are 12042 rows (genes) and 539 columns (samples), 
clustering the whole gene expression data matrix might be tedious.  
 
4.3.1 HIERARCHICAL CLUSTERING 
It is however important to first perform some analysis on the data matrix before carrying 
out hierarchical clustering. First, the data is filtered. Filtering is done with the gene filter 
package from the Bioconductor. It helps to remove genes that are uninteresting, and this 
reduces the number of rows (genes) in the data matrix while the number of columns 
(samples) remains the same. Next the correlation between samples are computer after 
finding the variance of the rows in the matrix, ordering the filtered data with the variance-
calculated to get the top 100 row (genes) with the highest variance and scaling the matrix. 
Scaling makes the data matrix to have mean of zeros and standard deviation of ones. The 
correlation heatmap is plotted to compare samples that are similar.  
 
The heat map is a fusion of a lot of different graphical display, developed by statisticians 
over 100 years ago. Also called cluster heat map is a diagram that shows at the same time 
the hierarchical cluster structures of row and column in data matrix. It consist of a colored 
rectangular blocks, which are shaded by a predefined color code and represents the values 
of the matrix element. The rows and columns of the shaded rectangular blocks are 
arranged such that rows and columns that are similar are next to one another and the 
block also has hierarchical cluster trees on its vertical and horizontal margins (L. Wilkinson 
and M. Friendly 2009). 
 
The correlation matrix is converted to a “dist” object and a dendogram is drawn with 
“ward.D” hierarchical clustering method.  The dendrogram thus helps to group the samples 
and the genes into two groups (i.e. group A and group B samples), which will be useful for 
class comparison analysis.  
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4.3.2 CLUSTER VALIDATION 
The result of a clustering analysis can be validated with an R package called “clValid”. The 
“clValid” R package contains several method employed in clustering result validation. It has 
three validation methods namely internal, stability, and biological validation measures. The 
”clValid” package main function is given as clVAlid(), this function thus allows the 
simultaneous selection of numerous clustering algorithms, validation measures, clusters 
number in a one time call in order to determine the best clustering method to use and the 
perfect number of clusters for the dataset. In addition, clValid package calculates biological 
validation measures automatically by employing the biological information the Gene 
Ontology (GO) database through Bioconductor annotation packages (G. Brock et al 2008).  
 
Cluster validation is of three different types namely internal, stability and biological 
validation. Internal validation is a clustering validation measure that takes as input the 
dataset and the number of clusters to assess clustering quality using the underlying 
information in the data.  In addition, the compactness, connectedness and separation of 
the cluster partitions are measured with internal validation. Compactness determines how 
homogenous clusters are by observing intra-cluster variance while separation estimates 
the distance between the centroids of the clusters and hence it evaluates separation 
between clusters. Compactness and separation are both combined in Dunn index and 
Silhouette Width, along side compactness and the three are displayed as internal validation 
measures result. The ratio of the minimum distance that exist between observations that 
doesn’t belong to the same cluster to the largest intra-cluster distance is given as the Dunn 
Index while the Silhouette Width measures an observation’s Silhouette value i.e. Silhouette 
value assign a value close to 1 for well clustered observations and a value close to -1 for 
badly clustered observations (G. Brock et al 2008).   
 
Stability validation measures compares how consistent clustering results are by comparing 
this result with the cluster obtained when the column is deleted one after the other. It is a 
special form of internal validation measure and it worked well for highly correlated data, 
such as that obtained from high-throughput experiment. The measures in stability 
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validation are the average proportion of non-overlap (APN), the average distance (AD), the 
average distance between means (ADM), and the figure of merit (FOM) (G. Brock et al 
2008). 
 
Biological validation measures the competence of a clustering algorithm to produce a 
result that is relevant biologically.  This measures finds application in microarray data, 
where the observations are represented as genes by using biological homogeneity index 
(BHI) and biological stability index (BSI).  BHI examines clusters biological homogeneity 
while BSI investigates the clustering consistencies for genes that perform similar biological 
functions (G. Brock et al 2008). 
 
4.4 CLASS COMPARISON ANALYSIS 
This analysis involves selecting genes that are differentially expressed from the gene 
expression data. This was done with fold change and t-test method.  
 
4.4.1 THE FOLD CHANGE METHOD 
The fold change method involves calculating the mean expression level for each condition 
and then selecting genes that has fold changes that are greater than an approximate 
threshold. The filtered data matrix is used to calculate the arithmetic means and the log 
fold change, which corresponds to the log ratio of the mean intensities of two groups of 
samples. The two groups of samples are obtained from the hierarchical clustering results 
since the samples are not predefined (S. Drăghici 2011). 
 
The result obtained here can be shown on a scatter plot, which is similar to a Minus-Add 
plot and has two lines that correspond to the threshold used. The scatter plots can be plot 
of log fold changes versus log intensities and log intensities of one group versus that of the 
other group (S. Drăghici 2011). 
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4.4.2 T-TEST METHOD  
The T-Test Method is a parametric method of selecting genes that are differentially 
expressed. This method deals with multiple testing issues which normally arises during 
microarray analysis by first filtering the genes from the gene expression data matrix. Gene 
filtering is done with the gene filter package and it helps to get rid of array spike control, 
remove probes with little irregularity among samples or those with low level of expression. 
Probes removal thus makes the number of hypothesis to be tested to reduce and also 
reduces the number of uninteresting, differentially expressed genes (S. Drăghici 2011). 
 
The t-test is carried out between the sample groups with the null hypothesis there is no 
particular gene on the array that is differentially expressed and an alternative hypothesis 
that the gene in question has a different expression level between the sample groups (A.L. 
Tarca et al 2008). After performing the t-test between the sample groups from the data 
matrix, the p-values obtained are plotted on a histogram. Multiple adjustments depend on 
the shape of the plot of p-value.  
 
In this study, differentially expressed genes are selected by combining the fold change and 
the t-test method using different thresholds for each method. This thus helps to get the 
genes that are truly differentially expressed. The data matrix obtained contains the truly 
differentially expressed genes, as its row and the samples remains its column.   
 
4.5 CLASS PREDICTION ANALYSIS 
Class prediction analysis comprise of creating of a classification function that can correctly 
deduce a patient biologic group or his diagnostics category based on the expression 
pattern of a tissue from the patient in question.  The phenotype classes are stated priori 
and this does not depend on the gene expression data, hence it a supervised analysis. The 
major steps in class prediction analysis are feature selection, selecting predictor function 
(classifier) and assessing classifier performance (R. Simon 2003). 
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The future selection step involves selecting genes that are differentially expressed from the 
expression data. These genes are informative and they are used in building the classifier (R. 
Simon 2003). Differentially expressed genes are obtained with the methods describes in 
section 3.3 above and the result from this section is adapted as the informative genes for 
this analysis. 
 
The selection of a predictor function (classifier) is the next step after feature selection. 
Several classifiers such as linear discriminant analysis, nearest neighbor predictor, logistic 
regression or support vector machine can be adopted depending on the problem at hand 
(R. Simon 2003). It should be noted that data must be first divided before a classifier can be 
used to build a model, thus classifier performance assessment is incorporated into the 
model-building algorithm.  
 
The KNN classifier is a straightforward algorithm that assembles all cases available and 
proceeds to categorize them using the majority vote of its k nearest neighbor. It thus 
classifies uncategorized data into groups that are well defined. The algorithm starts by 
creating the training and test set from the entire expression data set by dividing the data 
into two portions with larger path of the data as the training set and the rest as the test 
set. The KNN classifier is then used to train the model using classes from training sets and 
specifying the value of k as the number of samples in the expression set. KNN classifier 
selects the nearest neighbor using euclidean distance as its distance metric (B. Lantz 2015). 
 
Furthermore, the performance of the built model is displayed in a confusion matrix. The 
confusion matrix is build by the table() function in R. However the CrossTable() function 
from the gmodel package in R gives a more detailed confusion matrix called the 
contingency table. From this table, accuracy and error rate is computed in percentage. A 
high value of accuracy and low value of error rate, say 95% and 0.05% implies that the built 
classifier is nearly perfect. However, a low accuracy value and a high error rate indicate a 
poor classifier and the classifier has to be re-built (B. Lantz 2015). 
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4.6 ENRICHMENT ANALYSIS 
Enrichment analysis helps in obtaining biological significance in term of statistical 
significance and to interpret gene group in order to identify biological information for the 
event under study. Modular enrichment analysis is the method of enrichment analysis is 
employed and it involves using a list of differentially expressed genes to test multiple 
annotation term at once considering the relationship between each pair of terms 
(Mosquera Mayo and José Luís 2014).  
 
Gene list analysis is performed on PANTHER by first pasting or uploading a gene list into the 
database. The pasted gene list needs to be similar with the supported IDs (e.g. Ensemble 
Gene ID, Entrez Gene ID etc.) on PANTHER database and the uploaded list has to be a file, 
which is in a format recognized by the PANTHER database.  The list in question may be an 
identifier list, previously exported text search or a PANTHER generic mapping file. The next 
step involves selecting homosapiens as the organism of interest since the gene list is from 
human. Next, the analysis carried out is selected on the database as functional 
classification viewed in pie chart or bar chat. The result here is viewed as PANTHER GO-slim 
Biological Process which is the default Annotation and other Annotations such as PANTHER 
GO-slim Molecular Function, PANTHER GO-slim Cellular Component, PANTHER Protein 
Class and Pathway are obtained by using the drop down menu in the close to the 
Annotation data set. The chart showing the different 100% of the categories involves in 
each annotation analysis (PANTHER user manual 2015). 
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4.7 SURVIVAL ANALYSIS 
Survival analysis is carried out using the non-parametric method i.e. Kaplan-Mier method 
and plotting the resulting survival curve.  
 
The Kaplan-Mier method is the most wide used non-parametric method of analyzing 
survival data and is applicable to small, medium and large samples. It estimates survival 
function, probabilities and graphical representation of survival distribution by assuming 
that the censoring time does not depend on survival time (E.T. Lee and J.W. Wang 2003).  
 
First the clinical data is read into R and the columns that contain the important parameter 
for this analysis are noted.  These columns (event, time to event and sample ID) are 
extracted and used for plotting the Kaplan-Mier survival curve. The median survival times 
of the curves are computed and the curves are compared statistically with log-rank test. 
The comparison aims to determine if these curves are the same or not. In comparing 
survival curve with log-rank test, the following steps are involved. 
 
a. Define hypothesis and determine significant level 
 Ho  (Null hypothesis) - The survival curves from the two groups are identical 
 H1  (Alternate hypothesis) - The survival curves from the two groups are not 
identical (i.e. α = 0-05) (Lisa Sullivan 2016). 
 
b. Select appropriate statistics (Lisa Sullivan 2016). 
 The “survdiff” function from the survival package in R gives the result as chi-
square statistics with degree of freedom and resulting p-value. 
 
c. Define the decision rule to adopt 
 The critical value of chi-square distribution from chi-square table is for degree of 
freedom 1 (i.e. two group comparison) and α = 0-05. The chi-square critical value 
is 3.841 and the decision rule is to reject H0 if chi-square critical value is greater 
than > 3.841 (Lisa Sullivan 2016). 
 
d. Compute the test statistics by running the “survdiff” function and make conclusions. 
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4.8 RESULT VERIFICATION USING INDEPENDEDNT GBM DATASET 
The verification dataset is obtained from the Gene expression Omnibus (GEO) database of 
the National Center for Biotechnology Information (NCBI). The dataset has an accession 
number of GSE20736_RAW and contains 6 GBM tumor samples, which are obtained from 
the Affymetrix Human Genome U133 Plus 2.0 Array platform. The file containing these 
samples are downloaded as zipped filled, unzipped and read into R as raw CEL files. Probe 
effects (RLE & NUSE plots), intensity plot, and box plot are used to access the qualities of 
the 6 raw CEL files. These plots reveal that the CEL files are raw in nature.  
 
Furthermore, the CEL files are preprocessed using the rma() function, which performs 
background correction and normalization on the raw CEL files to give a normalized data. for 
The expr() function is applied to the normalized data to obtain the data matrix needed. The 
data matrix is in turn filtered in other to remove irrelevant genes.  Correlation matrix is first 
created to define relationships that exist between samples and dendrograms are drawn for 
both samples and genes to perform hierarchical clustering on samples and genes 
correlation matrices. Differentially expressed genes are then obtained in a similar way as 
explained in section 4.4 above. The verification process is carried out by transforming the 
differentially expressed genes into biological meaning with the help of the PANTHER 
database. The results from experimental data are compared with the one from here in 
terms of molecular function, biological process, cellular components and pathways in 
which both differentially expressed genes play different roles.  
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5. FINDINGS  
5.1 CLASS DISCOVERY ANALYSIS 
5.1.1 HIERARCHICAL CLUSTERING 
The data matrix derived from the gene expression matrix is clustered so that similar 
samples and genes are grouped together. It will be difficult to cluster the entire data matrix 
since the matrix has 12042 rows (genes) and 539 columns (samples). 
 
A filtered data with of 3128 rows (genes) and 539 columns (samples) is obtained after 
filtering. A sample-sample Pearson’s correlation matrix with 539 rows and 539 columns, 
that shows correlation between samples is obtained. This is done by finding and selecting 
the top 100 rows (genes) from the matrix with the highest variance. The result is ordered 
with the filtered data and finally scaled. A correlation heatmap is plotted using hierarchical 
clustering with ward’s method to compare samples that are similar. In figure 5.1 below, the 
red color specifies the samples that correlate positively with each other and it implies that 
there are highly correlating genes between this samples. On the other hand, the green 
color indicated samples that correlate. Positive correlation also indicates a high similarity in 
sample’s expressions within a group while negative correlation is the inverse. In addition, 
figure 5.1 also shows that samples are divided into two distinct clusters with each cluster 
having two sub-clusters each.  
 
Dendrograms are drawn for both genes and samples by performing hierarchical clustering 
on the correlation matrices that relate to the genes and samples respectively. Both 
dendrograms are shown in figures 5.2a and 5.2b respectively. From figure 5.2a, there are 
two sample groups with group A having 253 samples and group B having 286 samples. 
Figure 5.2b shows two gene groups with group A having 60 genes and group B having 40 
genes. Samples and gene group numbers are shown in table 4.1 below 
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GROUP SAMPLES GENES 
A 253 60 
B 286 40 
 
Table 5.1: Samples and Genes groups 
 
 
 
 
Figure 5.1: Correlation heatmap of data matrix 
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Figure 5.2A: Sample dendrogram 
 
 
 
Figure 5.2B: Gene dendrogram 
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5.1.2 CLUSTER VALIDATION WITH “CLVALID” R PACKAGE  
The result of samples and genes clustering is validated with an R package called “clValid”. 
For sampled clustering, the scaled data that has genes as its rows and samples as its 
column is transposed. The transpose is carried out since the “clValid” package performs 
row clustering. Hence the need to have a transposed scaled data, which has the samples as 
its rows and genes as its column. The clValid” function test for hierarchical and k-means 
clustering for both the samples and genes from the expression data matrix. The validation 
considers two to five clusters and the results are shown in table 5.2 and 5.4 below. 
 
 
S/N 
CLUSTERING 
METHOD 
VALIDATION 
PARAMETERS 
NUMBER OF CLUSTERS AND SCORES 
2 3 4 5 
 
 
 
1 
 
 
 
HIERARCHICAL 
CLUSTERING 
 
Connectivity 
 
11.2060   
 
14.9933   
 
17.8683   
 
25.1520 
 
Dunn 
 
0.4382 
 
0.4382 
 
0.4382 
 
0.4382 
 
Silhouette 
 
0.2589    
 
0.2410 
 
0.2056  
 
0.2024 
 
 
2 
 
 
K-MEANS  
CLUSTERING 
 
Connectivity 
 
157.0353 
 
145.5774 
 
160.9516  
 
167.7873 
 
Dunn 
 
0.35492 
 
0.3645 
 
0.3780    
 
0.3780 
 
Silhouette 
 
0.1316    
 
0.1372    
 
0.1278    
 
0.125 
 
Table 5.2: Sample cluster validation result 
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From table 5.2 above, a table showing the clustering method, numbers of clusters, 
validation parameters, and their scores is generated.  
 
 
S/N 
VALIDATION 
PARAMETERS 
 
SCORE 
CLUSTERING 
METHOD 
NUMBER OF 
CLUSTERS 
 
1 
 
Connectivity 
 
11.2060 
 
Hierarchical 
 
2 
 
2 
 
Dunn 
 
0.4382 
 
Hierarchical 
 
2 
 
3 
 
Silhouette 
 
0.2589 
 
Hierarchical 
 
2 
 
Table 5.3: Optimal scores for sample cluster validation 
 
From table 5.3 above, the three internal validation parameters give two clusters and 
suggest hierarchical clustering as the appropriate clustering technique for the data. Larger 
values of Dunn index and Silhouette width indicates a good cluster while a lower 
connectivity value indicates a good cluster. This means that the Dunn Index and Silhouette 
width internal validation parameters are maximized while the connectivity internal 
validation parameter is minimized. Hence, hierarchical clustering with two clusters gives a 
better performance. In addition, it is clear that the samples that appeared as the column in 
the transposed version of the scaled data has two clusters and hierarchical clustering is the 
appropriate clustering technique that should be employed in clustering the data.  Hence, 
the result obtained earlier with the dendrogram in section 5.1.1 has been validated.  
 
For gene clustering result validation, the same method is employed. The data matrix used 
here is the scaled data that has genes as its rows and samples as its column.  The result of 
genes clusters validation testing for hierarchical and k-means clustering for two to five 
clusters are shown in table 5.4 below.  
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S/N 
CLUSTERING 
METHOD 
VALIDATION 
PARAMETERS 
NUMBER OF CLUSTERS AND SCORES 
2 3 4 5 
 
 
 
1 
 
 
 
HIERARCHICAL 
CLUSTERING 
 
Connectivity 
 
2.9290 
 
13.9171 
 
16.8460 
 
19.7750 
 
Dunn 
 
0.5756 
 
0.2383 
 
0.2383 
 
0.2383 
 
Silhouette 
 
0.2246  
 
0.2342 
 
0.1876  
 
0.1727 
 
 
2 
 
 
K-MEANS  
CLUSTERING 
 
Connectivity 
 
30.7845 
 
33.0607 
 
43.9794 
 
50.0595 
 
Dunn 
 
0.2637   
 
0.2637 
 
0.3438 
 
0.3328 
 
Silhouette 
 
0.2379   
 
0.2381  
 
0.1799   
 
0.1616   
 
Table 5.4: Gene cluster validation result 
 
From table 5.4 above, a table showing the clustering method, numbers of clusters, 
validation parameters, and their scores is generated. Larger values of Dunn index and 
Silhouette width indicates a good cluster while a lower connectivity value indicates a good 
cluster. This means that the Dunn Index and Silhouette width internal validation 
parameters are maximized while the connectivity internal validation parameter is 
minimized. It is clear from table 5.5 below that Connectivity and Dunn validation 
parameters give two clusters and suggest hierarchical solution as the appropriate 
clustering technique while the Silhouette validation parameter gives three clusters and 
suggest Kmeans clustering as the appropriate clustering technique that should be adopted. 
Since two validation parameters gives two clusters and suggest hierarchical clustering as 
the appropriate clustering, it implies that hierarchical clustering with two clusters gives a 
better performance compared to the Kmeans clustering with five clusters. Hence, the 
result obtained from dendrogram in section 5.1.1 has been validated.  
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S/N 
VALIDATION 
PARAMETERS 
 
SCORE 
CLUSTERING 
METHOD 
NUMBER OF 
CLUSTERS 
 
1 
 
Connectivity 
 
2.9290 
 
Hierarchical 
 
2 
 
2 
 
Dunn 
 
0.5756 
 
Hierarchical 
 
2 
 
3 
 
Silhouette 
 
0.2381 
 
Kmeans  
 
3 
 
Table 5.5: Optimal scores for genes cluster validation 
 
5.2 CLASS COMPARISON ANALYSIS 
5.2.1 FOLD CHANGE METHOD 
Fold change method is used to find the differentially expressed genes between the two 
sample groups obtained from hierarchical clustering analysis. With an absolute fold change 
greater than 1.0, the top 20 differentially expressed obtained are shown in table 5.6 below.  
 
4.2.2 T-TEST METHOD 
The t-test method is used to find the differentially expressed genes between sample groups  
obtained from hierarchical clustering analysis. The p-values obtained from t-test are 
plotted on the histogram as shown in figure 5.3 and the plot thus determines the need for 
p-value adjustment (multiple testing). The plot in figure 5.3 shows the p-value obtained 
from the t-test analysis with the horizontal axis showing the p-values and the vertical axis 
showing he number of times each p-value occurs. It is clear from this figure that the set of 
p-values obtained gives us evidence against the null hypothesis. This is because the flat 
distribution to the right of the figure contains the entire null p-values (null hypotheses), 
which are distributed uniformly between 0 and 1. In addition, the peak to the left (close to 
zero) contains the alternative hypotheses. Since majority of the null hypotheses are 
obtained at low p-values, then all p-values less than 0.05 are called significant. The top 20 
genes with a p-value less than 0.05 are shown in table 5.6 below.  
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                          Figure 5.3: Histogram of p-values from t-test analysis 
 
However, genes that are truly differentially expressed are obtained by a fold-change cutoff 
greater than 1.0 and a p-value less than 0.05. A total of 1351 genes are obtained as 
differentially expressed genes between the two sample groups. The top 20 differentially 
expressed genes are shown in table 5.6 below. From the table, some of the genes appeared 
as fold change genes and t-test genes simultaneously. Hence, this combination gives a 
better result because both technical and biological significance are considered at the same 
time.  
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S/N 
FOLD CHANGE 
GENES 
T-TEST 
GENES 
FOLD CHANGE AND T-TEST 
DE GENES 
1.  UBE2Q1 RNF11 RNF14 
2.  RNF10 RNF13 UBE2Q1 
3.  RNF11 PMM1 RNF10 
4.  RNF13 ASS1 RNF11 
5.  NDP NID2 RNF13 
6.  PMM1 ZC3H14 NDP 
7.  ZC3H15 DHX9 PMM1 
8.  ZC3H14 GRINA ASS1 
9.  RNF111 NUP93 NID2 
10.  NACAP1 OPA1 ZNF706 
11.  DHX9 RAB40B ZC3H15 
12.  XPC KIAA0831 ZC3H14 
13.  GRINA UGCG RNF111 
14.  SP3 ATP2A2 NACAP1 
15.  NUP93 RIT1 DHX9 
16.  GOLIM4 ITGA7 XCP 
17.  OPA1 DENND4B GRINA 
18.  RAB40B SWAP70 SP3 
19.  KIAA0831 PHLDA1 NUP93 
20.  ATP2A2 GAP43 GOLIM4 
 
Table 5.6: Differentially expressed genes from experimental data 
 
For the validation data, the same method used in section 5.2.1 and 5.2.2 was repeated and 
the lists of differentially expressed genes are shown in table 5.7 below. 
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S/N 
FOLD CHANGE 
GENES 
T-TEST 
GENES 
FOLD CHANGE AND T-TEST 
DE GENES 
1.  DDR1  EPHB3 DDR1 
2.  RFC2   C4orf33 RFC2 
3.  PAX8    C6orf141 PABX 
4.  UBA7        JAK1 UBA7 
5.  EPHB3 CARD16 EPHB3 
6.  ESRRA CARD16 ESRRA 
7.  SCARB1    CASP1 SCARB1 
8.  TTLL12    TLR4 TTLL12 
9.  MAPK1   RAB46 MAPK1 
10.  PXK      ALKBH5 PXK 
11.  C9orf30     NFX1 PXK 
12.  AFG3L1   STK38 C9orf30 
13.  PIGX   FOXC1 AFG3L1 
14.  SLC39A13      NPB PIGX 
15.  NEXN ZNF791 SLC39A13 
16.  MFAP3      ZNF791 NEXN 
17.  CNOT7   TMTC4 MFAP3 
18.  CRYZL1 CLDND1 CNOT7 
19.  LEAP2         CENPL CRYZL1 
20.  C4orf33   TIPRL LEAP2 
 
Table 5.7: Differentially expressed genes for independent GBM data (validation data).  
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5.3 CLASS PREDICTION 
Class prediction analysis intends to build a model to predict the class membership of the 
sample groups obtained from hierarchical clustering analysis. First, features are selected, 
then a classifier is chosen. The chosen classifier is used to build a model, and finally the 
built model evaluated by computing model assessment parameters such as accuracy, error, 
sensitivity, specificity etc. This analysis gives a contingency table (confusion matrix) as 
shown in table 5.8 below. 
 
                                                                              FORESIGHTED VALUE 
                                                                          Negative               Positive 
 
                                        Negative                
                 ORIGINAL 
                   VALUE 
         Positive 
 
Table 5.8: Contingency table 
 
This analysis is done with the data matrix obtained from class comparison analysis. Since 
the data matrix contains the differentially expressed genes as its rows and the samples as 
its column, then it is transposed in other to have the samples as columns and the 
differentially expressed genes as rows. Samples are first splitted into training and testing 
sets. Two-third of the total number of samples (539 samples) are used to create the 
training set (359 samples) while one-third of the samples give the testing set (180 samples). 
Then a KNN classifier is adopted and the value of K used is the odd number close to the 
square root of the training set size (i.e. √359 ≈ 19). Training sets are used in building the 
model while the training sets are used in testing the built model. Table 5.9 below shows 
the True Negative (TN), False Negative (FN), True Positive (TP) and False Positive (FP) values 
obtained with K= 19. It should be noted that the total number of items in table 5.9 equals 
the number of items in the training set.  
 
T.N 
True Negative 
F.P 
False Positive 
F.N 
False Negative 
T.P 
True Positive 
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                        Table 5.9: KNN Contingency table for K of 19 
 
Other K values are also tested in the other to check for the K value that gives an improved 
model. Their results are shown in table 5.10 below. 
 
S/N K-VALUES TESTING CLASS/ KNN PREDICTION 
 
1 
 
17 
 SAMPLE A SAMPLE B 
SAMPLE A 66 29 
SAMPLE B 6 79 
 
2 
 
15 
 SAMPLE A SAMPLE B 
SAMPLE A 69 26 
SAMPLE B 7 78 
 
3 
 
13 
 SAMPLE A SAMPLE B 
SAMPLE A 69 24 
SAMPLE B 6 79 
 
4 
 
11 
 SAMPLE A SAMPLE B 
SAMPLE A 71 24 
SAMPLE B 5 80 
 
5 
 
9 
 SAMPLE A SAMPLE B 
SAMPLE A 69 26 
SAMPLE B 7 78 
 
6 
 
7 
 SAMPLE A SAMPLE B 
SAMPLE A 69 26 
SAMPLE B 6 79 
 
7 
 
 
5 
 SAMPLE A SAMPLE B 
SAMPLE A 68 27 
SAMPLE B 9 76 
 
Table 5.10: Contingency table for different values of K. 
 KNN PREDICTION 
TESTING CLASS SAMPLE A SAMPLE B 
SAMPLE A 64 31 
SAMPLE B 6 79 
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The best K value is however selected form table 5.10 above and it is used for model 
performance assessment. It is clear from table 5.10 below that the K value of 11 gives a 
better result since it gives more true negatives and true positives, as well as lower false 
negative and false positives, when compared with other K values results. Hence it is 
adopted and used for model performance assessment. The contingency table for model 
with K value of 11 is shown in figure 5.11 below. 
  
           Cell Contents 
N 
N / Row Total 
N / Col Total 
N / Table Total 
                                                    
                            Total Observations in Table:  180 
  
KNN PREDICTION 
 
TESTING CLASS 
 
SAMPLE A 
 
SAMPLE B 
 
ROW TOTAL 
 
 
SAMPLE A 
71 
0.747 
0.934 
0.394 
24 
0.253 
0.231 
0.133 
95 
0.528 
 
SAMPLE B 
5 
0.059 
0.066 
0.028 
80 
0.941 
0.767 
0.444 
85 
0.472 
COLUMN 
TOTAL 
76 
0.422 
104 
0.578 
180 
 
Table 5.11: Contigenct table for K value of 11 
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The following model performance parameters are computed from the values obtained in 
table 4.11 above. 
 
A. ACCURACY 
Accuracy = (T.P + T.N) / (T.P + T.N + F.N + F.P) 
                      = (80 + 71) / (80 + 71 + 5 + 24) = 151/180 
                      = 0.839 
                      = 83.9% 
 This implies that the classifier is 80% accurate. 
 
B. ERROR RATE 
Error rate = 1 - Accuracy 
                  = 1 – 0.839 
                  = 0.161 
                  = 16.1% 
 
The error rate here is 16.1% and it can be attributed to system bias.  
         
C. SENSITIVITY 
 Sensitivity = T.P / (T.P + F.N) 
                     = 80 / (80 + 5)  
                     = 0.941 
                     = 94.1% 
 
This implies that 94.1% of sample A were correctly classified. This mean that 80 samples 
out of 85 samples classified as sample A are correctly classified while 5 samples are 
incorrectly classified.  
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D. SPECIFICITY 
Specificity = T.N / (T.N + F.P) 
                   = 71 / (71 + 24) 
                   = 0.747 
                   = 74.7% 
 
This implies that 74.7% of sample B were correctly classified. This mean that 71 sample out 
of 95 samples classified as sample B is correctly classified while 24 samples are incorrectly 
classified.  
 
E. PRECISION (Positive Predictive Value) 
Precision  = T.P / (T.P + FP) 
                  = 81 / (81 + 24) 
                  = 0.771 
                  = 77.1% 
 
Since precision defines how exact a classifier is, it is clear that a classifier with a precision 
value of 0.771 (77.1%) is almost perfect and has a lot of true positives. 
 
F. RECALL (SENSITIVITY) 
Recall  = T.P / (T.P + F.N) 
             = 80 / (80 + 5)  
             = 0.941 
             = 94.1% 
 
Since recall measures how complete a classifier is, it implies that the classifier above is 
94.1% complete.  
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G.  F-MEASURE  
F-Measure = (2 * PRECISION * RECALL) / (PRECISION + RECALL) 
                    = (2 * 0.771 * 0.941) / (0.771 + 0.941) 
                    = 0.848 
                   = 84.8% 
This implies that the performance of the classifier is 84.8%, which is nearly effective. 
 
In summary, all the measures above have values close to 1. Based on this analysis, 
separation of two classes is established.  
 
5.4 ENRICHMENTS AND FUNCTIONAL ANALYSIS  
The list of differentially expressed genes is translated into biological terms with PANTHER 
for both the experimental and verification data and the results obtained are shown below. 
 
5.4.1 MOLECULAR FUNCTION (MF) 
The molecular functions in which the differentially expressed genes from both data 
perform are shown in the table 5.12 below. It is observed that 32 genes out of the total 50 
differentially expressed genes from the experimental data performs molecular functions 
while 30 genes out of the total 50 DE genes from the validation data performs molecular 
function. Also the DE genes from both data perform similar molecular functions (i.e. five). 
From the results displayed in from table 5.12, analysis result is validated.   
 
5.4.2 BIOLOGICAL PROCESS (BP) 
The biological processes in which the differentially expressed genes from both data play 
roles are shown in the table 5.13 below. It is observed that 80 genes out of the total 50 
differentially expressed genes from the experimental data perform molecular functions 
while 60 genes out of the total 50 DE genes from the validation data play role in biological 
processes. It implies that some genes are involved in more than one biological process for 
both data. Also the DE genes from both data are involved in similar biological processes 
(i.e. ten) except for locomotion (GO:0040011) biological process, which is performed by 
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NEXN and JAK1 genes in the validation data. From the results displayed in from table 5.13, 
analysis result is validated.   
 
5.4.3 CELLULAR COMPONENT 
The differentially expressed genes from both data are part of the cellular components 
shown in the table 5.14 below. It is observed that 40 out of 50 differentially expressed 
genes from the experimental data are part of cellular components and it implies that some 
genes are part of different cellular components. For the validation data, 31 out of 50 DE 
genes are part of different cellular components shown in table 5.14 below. Also the DE 
genes from both data are part of similar cellular components (i.e. five), except for Synapse 
(GO:0045202) cellular component, which is present in the experimental data and 
extracellular region (GO:0005576) present in validation data. From the results displayed in 
from table 5.14, analysis result is validated.   
 
5.4.5 PATHWAY 
 
The pathways in which the differentially expressed genes from both data play roles are 
shown in the table 5.15 below. It is observed that 29 genes out of the total 50 differentially 
expressed genes from the experimental data play roles in the pathway while 38 genes out 
of the total 50 DE genes from the validation data play roles in the pathway. Also the DE 
genes from both data play roles in similar pathways (i.e. seven) most of which are signalling 
pathways. In addition, the other pathways from both data overlap as shown in table 5.15. 
The major pathways in GBM reported by M. Nakada et al 2011 are all present in the 
pathways discovered in the experimental data column of table 5.15. Hence the result from 
this analysis is validated.  
 
 
 
 
 
  85 
 
Table 5.12: Molecular functions and their genes for experimental and validation data 
 
 
 
 
 
 
 
 
DATA EXPERIMENTAL DATA VALIDATION DATA 
(INDEPENDENT GBM DATASET) 
S/N MF GENES MF GENES 
1 Binding 
(GO:0005488) 
SP3, OPA1, SMAD4, 
CKS1B, PREB, 
SMAD1, FBL, RIT1, 
XPC, RNF14, RIT1, 
SWAP70, NACAP1, 
ZC3H15, ZC3H14 
Binding 
(GO:0005488) 
NEXN, TRNT1, PAX8, 
MEGF11, JAK1, 
ESRRA, RFC2, PLCD3, 
STX6 
2 Catalytic activity 
(GO:0003824) 
ASS1, DHX9, SPTLC1, 
OPA1, CKS1B, 
PMM1, FBL, CHST7, 
RIT1, UBE2Q1, 
UGCG, CHST2, 
ATP2A2 
 
Catalytic activity 
(GO:0003824) 
CASP1, HS6ST2, 
GAMT, TRNT1, 
CRYZL1, POLR2J3, 
JAK1, MAPK1, 
LACTB, TTLL12, 
CNOT7, RFC2, 
PLCD3, ATAD3A, 
UBA7, PRUNE2 
 
3 Receptor activity 
(GO:0004872) 
 
GRINA Receptor activity 
(GO:0004872) 
 
TLR4, SCARB1 
 
4 Structural 
molecule activity 
(GO:0005198) 
 
 
OPA1, NUP93 Structural 
molecule activity 
(GO:0005198) 
 
 
TTLL12, MFAP3 
5 Transporter 
activity 
(GO:0005215) 
 
ATP2A2 Transporter 
activity 
(GO:0005215) 
 
SLC39A13 
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DATA EXPERIMENTAL DATA VALIDATION DATA 
(INDEPENDENT GBM DATASET) 
S/N BP GENES BP GENES 
1 Biological 
adhesion 
(GO:0022610) 
 
ITGA7, RIT1, COL4A1, 
COL4A2, ITGAV 
Biological 
adhesion 
(GO:0022610) 
 
SCARB1 
2 Biological 
regulation 
(GO:0065007) 
GRINA, RNF14, 
RAB40B, ATP2A2 
Biological 
regulation 
(GO:0065007) 
 
NEXN, CASP1, 
SLC39A13, JAK1 
3 Cellular 
component 
organization or 
biogenesis 
(GO:0071840) 
OPA1, FBL, COL4A1, 
COL4A2, RAB40B, 
NUP93 
Cellular 
component 
organization or 
biogenesis 
(GO:0071840) 
 
NEXN, STX6 
4 Cellular process 
(GO:0009987) 
ASS1, DHX9, SP3, 
OPA1, SMAD4 
CKS1B, RNF11, 
SMAD1, FBL, CHST7, 
RNF111, RIT1, 
COL4A1, XPC, 
ATP6V0E2, RNF14, 
COL4A2, UGCG, RIT1, 
CHST2, RAB40B, 
ZC3H14, ATP2A2, 
NUP93 
 
Cellular process 
(GO:0009987) 
NEXN, CASP1, 
HS6ST2, GAMT, 
SCL39A13, TLR4, 
MEGF11, POLR2J3, 
JAK1, MAPK1, ESRRA, 
SCARB1, CNOT7, 
RFC2, PLCD3, MFAP3, 
UBA7, PRUNE2, STX6 
5 Developmental 
process 
(GO:0032502) 
 
COL4A1, UBE2Q1, 
RIT1 
Developmental 
process 
(GO:0032502) 
NEXN, CASP1, 
CRYZL1, PAXB, JAK1, 
EPHB3, PRUNE2 
6 Immune system 
process 
(GO:0002376) 
COL4A1, COL4A2, 
SWAP70 
Immune system 
process 
(GO:0002376) 
JAK1, MAPK1 
7 Localization 
(GO:0051179) 
 
OPA1, PREB, RIT1, 
RAB40B, NUP93 
Localization 
(GO:0051179) 
NEXN, JAK1, KLC3, 
STX6 
8 Metabolic process 
(GO:0008152) 
 
 
 
ASS1, DHX9, SPTLC1, 
SP3, SMAD4, RNF11, 
PREB, PMM1, 
SMAD1, FBL, CHST7, 
RNF111, DENND4B, 
Metabolic process 
(GO:0008152) 
HS6ST2, GAMT, 
TRNT1, CRYZL1, PAXB, 
POLR2J3, JAK1, 
TTLL12, CNOT7, RFC2, 
PLCD3, UBA7, 
  88 
 
Table 5.13: Biological Processes and their genes for experimental and validation data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 UBE2Q1, UGCG, 
RIT1, SWAP70, 
NACAP1, CHST2, 
ZC3H15 ZC3H14, 
ATP2A2 
PRUNE2 
 
 
9 Multicellular 
organismal 
process 
(GO:0032501) 
 
RIT1, COL4A1, 
RAB40B 
 
Multicellular 
organismal 
process 
(GO:0032501) 
 
NEXN, TLR4 
 
10 Response to 
stimulus 
(GO:0050896) 
 
RNF111, XCP, RIT1 Response to 
stimulus 
(GO:0050896) 
CASP1, JAK1, MAPK1, 
RFC2 
 
 
 
 
 
 
 Locomotion 
(GO:0040011) 
 
NEXN, JAK1 
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DATA EXPERIMENTAL DATA VALIDATION DATA 
(INDEPENDENT GBM DATASET) 
S/N CC GENES CC GENES 
1 Cell part 
(GO:0044464) 
ASS1, DHX9, GAP43, 
SP3, OPA1, FBL, 
RNF111, XPC, RNF14, 
RIT1, RAB40B, 
ZC3H14, ATP2A2, 
NUP93 
 
Cell part 
(GO:0044464) 
NEXN, CASP1, 
GAMT, SLC39A13, 
POLR2J3, JAK1, 
TTLL12, CNOT7, 
RFC2, UBA7, 
PRUNE2, STX6 
2 Extracellular matrix 
(GO:0031012) 
COL4A1 COL4A2 Extracellular matrix 
(GO:0031012) 
MEGF11 
3 
 
 
 
 
Macromolecular 
complex 
(GO:0032991) 
 
DHX9, FBL, XPC, 
RNF14, NUP93 
Macromolecular 
complex 
(GO:0032991) 
 
CASP1, POLR2J3, 
CNOT7, RFC2, STX6 
4 Membrane 
(GO:0016020) 
CHST7, FAM134A, 
CHST2, RAB40B, 
ATP2A2, NUP93 
 
Membrane 
(GO:0016020) 
 
 
SLC39A13, JAK1, 
STX6 
5 Organelle 
(GO:0043226) 
GAP43, SP3, OPA1, 
FBL, RNF111, XPC, 
RIT1, RAB40B, 
ZC3H14, ATP2A2, 
NUP93 
Organelle 
(GO:0043226) 
NEXN, GAMT, 
SLC39A13, TTLL12, 
KLC3, RFC2, UBA7 
6 Synapse 
(GO:0045202) 
GAP43, RBA40B Extracellular region 
(GO:0005576) 
TLR4, MEGF11, 
MFAP3 
 
 
 
Table 5.14: Cellular components and their genes for experimental and validation data 
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DATA EXPERIMENTAL DATA VALIDATION DATA 
(INDEPENDENT GBM DATASET) 
S/N PATHWAY GENES PATHWAY GENES 
1 Apoptosis signaling 
pathway (P00006) 
IGF2R Apoptosis signaling 
pathway (P00006) 
MAPK1 
2 CCKR 
signaling map 
(P06959) 
SP3, ITGAV CCKR 
signaling map 
(P06959) 
 
MAPK1 
3 Gonadotropin-
releasing hormone 
receptor pathway 
(P06664) 
SMAD4, 
SMAD1 
Gonadotropin-
releasing hormone 
receptor pathway 
(P06664) 
 
MAPK1, ESRRA 
 
4 Histamine H1 
receptor mediated 
signaling pathway 
(P04385) 
 
HRH1 Histamine H1 
receptor mediated 
signaling pathway 
(P04385) 
 
PLCD3 
5 Insulin/IGF pathway-
mitogen activated 
protein kinase 
kinase/MAP kinase 
cascade (P00032) 
IGF2R Insulin/IGF pathway-
mitogen activated 
protein kinase 
kinase/MAP kinase 
cascade (P00032) 
MAPK1 
6 Integrin 
signalling pathway 
(P00034) 
COL4A5, ITGA7, 
COL4A1, 
COL4A2, ITGAV 
Integrin 
signalling pathway 
(P00034) 
MAPK1 
7 TGF-beta 
signaling pathway 
(P00052) 
SMAD4, 
SMAD1 
TGF-beta 
signaling pathway 
(P00052) 
MAPK1 
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                 Table 5.15: Pathways and their genes for experimental and validation data 
 
 
 
 
 
 
 
 
 
 
8 ALP23B 
signaling pathway 
(P06209) 
SMAD4 5HT2 type receptor 
mediated signaling 
pathway (P04374) 
PLCD3 
9 Activin beta Signaling 
pathway (P06210) 
SMAD4 Alpha adrenergic 
receptor signaling 
pathway (P00002) 
 
STX6 
10 BMP/activin signaling 
pathway-drosophila 
(P06211) 
SMAD4 Angiogenesis 
(P00005) 
JAK1, MAPK1, 
EPHB3 
11 DPP 
signaling pathway 
(P06213) 
SMAD4 EGF receptor signaling 
pathway (P00018) 
 
MAPK1 
12 DPP-SCW 
signaling pathway 
(P06213) 
 
SMAD4 Endothelin signaling 
pathway (P00019) 
 
MAPK1 
13 Insulin/IGF pathway-
protein kinase B 
signaling cascade 
(P00033) 
IGF2R Interleukin signaling 
pathway (P00036) 
 
JAK1, MAPK1 
14 Wnt 
signaling pathway   
(P00057) 
 
SMAD4, SMAD1 JAK/STAT 
signaling pathway 
(P00038) 
JAK1 
15 Mannose metabolism 
(P02752) 
PMM1 PDGF signaling 
pathway (P00047) 
 
JAK1, MAPK1 
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5.5 SURVIVAL ANALYSIS 
The data frame used for this analysis is obtained by merge the clinical data, which contain 
the patient information and data matrix, which contains the expression values. The two 
data thus has a column (Sample ID) in common, hence the merging was successful.  The 
resulting data frame thus contains as its columns the sample ID, event and time to event 
and as rows the patient sample ID. From this data frame, a survival object is created with 
event, time to event and sample ID. 
 
A survival curve is plotted with a Kaplan-Meier estimate of 95% confidence bounds as 
shown in figure 5.4 below. The curve estimates survival throughout event time and event 
till the patients drop out of the study. The vertical line of this curve gives the proportion of 
people surviving while the horizontal axis represents the time (in days) after the beginning 
of the experiment. It is clear from figure 5.4 below that the survival curves for patients with 
sample A tumor and patients with sample B tumor are almost smooth, which implies that 
the curve accurately explains the death time.  
 
Also the curves have median survival times (i.e. the time at which the proportion surviving 
is 50%) of 372 days (approximately 12 months) for sample A tumor and 298 days  
(approximately 10 months) for sample B tumor as shown in table 5.16 below. This thus 
implies that the survival of patients with GBM is below a year and this thus confirms that 
the tumor is very aggressive. Hence, the chance of surviving GBM is very low.    
 
Sample ID Events Events Median 0.95 LCL 0.95 UCLL 
Sample A 245 245 372 327 432 
Sample B 279 279 298 268 345 
 
Table 5.16: Median survival time of GBM patients samples 
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Figure 5.4: Kaplan-Mier Survival Plot 
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5.6.1 SURVIVAL CURVE COMPARISON 
Observing the survival curves physically and computing their median survival is not enough 
to compare survival curve from two groups. A statistical approach, which involves the use 
of log-rank test, is employed to compare the curves in question. The result obtained after 
running the “survdiff” function from the survival package in R is shown in table 5.17 below. 
 
 
Sample ID Events Observed Expected (O-E)^2/E (O-E)^2/V 
Sample A 245 245 265 1.48 3.04 
Sample B 279 279 259 1.52 3.04 
 
Table 5.17: Log-rank test result 
 
Also the function gives a chi-square value of 3.000 on 1 degrees of freedom and an 
associated p-value of 0.0814. The chi-square value is less than 3.841, hence the null 
hypothesis that the survival curves for the two sample groups are identical. This implies 
that there is no statistical significant evidence at α = 0.05 that the survival time between 
the two sample groups (sample A and sample B) are different.  
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6. DISCUSSIONS  
6.1 EVALUATION OF STUDY METHODS 
This study aims to obtain sample and gene subgroup from data matrix, identify genes that 
are differentially expressed between samples, predict sample membership. In addition, it 
also aims to transform differentially expressed genes into biological meaning and verify 
analysis results with an independent GBM dataset.  
 
To achieve this, class discovery analysis (clustering) was performed on a filtered data 
matrix. This analysis helps in grouping the samples and or genes into subgroup (clusters) 
and the result from here can be adopted in class comparison and class prediction analysis. 
Since clustering works for any data even if there are no relationships between the terms in 
the data, it is important to perform this analysis in the best possible way. In order to get a 
perfect cluster from a data matrix, the correction between data column (samples) are 
evaluated and the resulting matrix is a sample-sample correlation matrix.  The dendrogram 
plot of this correlation matrix gives the real relationship that exists between samples and 
the subgroups are identified easily along side the number of elements in each subgroup. 
The same approach is used to obtain a gene-gene correlation matrix. Unlike the use of 
heatmap for hierarchical clustering, the correlation matrix approach is very reliable since it 
gives a better result than the former.  
 
The result from class discovery analysis was verified by the “clValid” R package with the 
aim of determining best number of cluster and assessing the performance of the method 
adopted. The package thus gives an internal validation measure of two-cluster solution and 
it suggests hierarchical clustering as the best method to be adopted in both sample and 
gene clustering. The result from the “clValid” R package conforms with that obtained from 
the class discovery analysis carried out in this study. The class discovery analysis reveals 
that GBM was grouped into two distinct clusters and each cluster has two sub-clusters. This 
indicates that GBM are of four subtypes. 
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Class comparison analysis aims to find genes that are differentially expressed between two 
conditions (samples) in a data matrix. This analysis somewhat depends on class discovery 
analysis, which gives insight into the subgroups that might be present in the data matrix. 
The analysis was carried out with fold change and t-test methods using a filtered data 
matrix. Filtering is done with gene filter package in R with the aim of removing genes with 
low expression value. The fold change method evaluates the mean of the expression level 
between the two-sample subgroups defined in class discovery analysis. The genes with a 
fold change greater than an absolute fold change (a.f.c of 1.0) threshold are selected as the 
genes that are differentially expressed between both sample subgroups. The value of 
absolute fold change mean is chosen arbitrarily and different value of it can be tested. It 
should be noted that the bigger the absolute fold change value, the lower the number of 
genes that will be selected as differentially expressed.  
 
The t-test method selects differentially expressed genes between the sample subgroups 
obtained in class discovery analysis by calculating their p-values. Since a filtered matrix is 
used for this analysis, the problem of multiple testing has been dealt with. The histogram 
of the p-value obtained from this analysis reveals that there is evidence against the null 
hypothesis. The differentially expressed genes are obtained by calling all p-values less than 
0.05 significant.  However, the truly differentially expressed genes are obtained by a fold-
change cutoff greater than 1.0 and a p-value less than 0.05. A total of 1351 genes are 
obtained as differentially expressed genes between the two sample groups. 
 
Class prediction analysis predicts the membership of the sample group obtained from class 
discovery analysis by using the data matrix obtained after class comparison analysis. This 
matrix was transposed so that the samples appear as the rows and the DEGs appear as the 
column. KNN classifier was used to build the model and different K values are used to 
search for the best performing model. The performance of the selected model is assessed 
by computing accuracy, error rate, sensitivity, specificity, precision, recall etc. 
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Functional and pathway enrichment analysis gives the biological interpretation to the 
differentially expressed genes obtained from class comparison analysis. These genes are 
pasted into PANTHER database and the Molecular Function (MF), Biological Process (BP), 
Cellular Component (CC) and Pathways in which these genes plays significant role are 
obtained.  
 
Results from the functional and pathway enrichment analysis in this study were validated 
with an independent GBM dataset from GEO. The same analysis steps were repeated for 
the independent dataset and the functional and pathway enrichment analysis was 
compared. The two results shows similar Molecular Function (MF), Biological Process (BP), 
Cellular Component (CC) and Pathways and this thus validates the results obtained in this 
study. 
 
The aggressiveness of GBM was predicted by computing the survival of patients using both 
the clinical data matrix, which contains vital patient information and expression data 
matrix, which contains patients sample ID. Non-parametric survival method that involves 
the plot of Kaplan-Mier curve is adopted. First a new data frame, which has as its columns; 
event, time to event, and patients sample ID is obtained from the clinical data. A survival 
object is then created from the data frame with event, time to event and patient sample ID 
with the aim of predicting the aggressiveness of GBM using patient sample ID classification 
obtained from hierarchical clustering analysis. It was observed that median survival time 
for patients with sample A is 12 months and that for patients with samples B is 10 months. 
This implies that median survival of patients with GBM is under 1 year and this thus 
confirms the tumor aggressiveness. The survival curve for patients with samples A is 
compared with the curve for patients with samples B using log-rank test. The test indicates 
that the survival curves are identical.  
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6.2 ANALYSIS RESULTS VERSUS RESULTS FROM PREVIOUS STUDIES  
The results from this study are broadly consistence with those achieved from previous 
studies. Sample-sample correlation matrix from this study gives two distinct clusters, which 
are made up of two sub-clusters each and this indicates that GBM are of four subtypes.  
Pearson correlation analysis was performed on 173 GBM samples from an mRNA 
expression dataset obtained TCGA website and the result gives two distinct clusters, which 
are made up of four different sub-clusters and that suggests that GBM is made of four 
distinct subtype (D. Renu et al 2015). In addition, it was also establish that GMB has four 
subtypes according to R.G.W. Verhaak et al (2010). 
 
Differentially expressed genes in this study were selected by combining fold change and T-
test method with different threshold. Although the issue of plotting p-value histogram to 
determine whether to perform multiple testing and to select p-value threshold has not 
been proper addressed. This study however suggests that the shape of the p-value 
histogram obtained goes a long way in determining the p-value threshold to be employed. 
Huggins et al. (2008) adopts a fold change of 1.3 and a p-value less than 0.2 to find 
differentially expressed genes and this is similar to what is done in this study. 
  
The pathways in which the differentially expressed genes from this analysis play significant 
roles have been reported in previous studies. Apoptosis signaling (cell death), integrin 
pathway (Angiogenesis), TGF and IGF signalling pathways, MAPK pathway are the pathways 
found in GBM reported by M. Nakada et al (2011). In addition, Marina M. Marelli et al 
(2009) reported that Receptors for gonadotropin-releasing hormone (GnRH) is present in 
glioblastoma tissue. Yeri Lee et al (2016) reported that the deregulation of WNT signalling 
is related to glioblastoma.  
 
This study also indicates that the median survival of GBM patients irrespective of the 
patients sample ID is under 1 year and this thus confirms the aggressiveness of GBM. 
Previous studies such as Michael Henriksen et al (2014) reported that GBM patients has 
median survival of less than 1 year while Azizul Haque et al (2011) reported that the 
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median survival of glioblastoma patients is between 10-12 months. These statements thus 
support the result obtained from this study. 
 
6.3 FURTHER RESEARCH WORK  
The analysis of GBM data has mainly addressed class discovery, class comparison, class 
prediction, and survival analysis while the identification of the molecular subtype in GBM 
has been neglected. In the future, analysis of GBM data should aim to identify and 
distinguish molecular subtype in GBM with R and Bioconductor tools.  
 
Also, in the selection of differentially expressed genes with t-test method, the shape of the 
p-value histogram play a huge role in determining the significant level to adopt and it also 
give information on the need for multiple testing. Future research work should consider 
the need for P-value histogram after t-test analysis so as to ascertain the need for multiple 
testing and to determine the accurate significance level.  
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7. CONCLUSION 
The true relationship that exists between samples and or genes in a gene expression data 
matrix can be best revealed with a sample-sample (or gene-gene) correlation matrix. The 
methods used in selecting differentially expressed genes from the experimental and 
validation datasets perform better because combining two methods gives better results. 
The use of PANTHER database helps to transform DEGs into biological information. The 
information from both datasets are compared in term of Molecular Functions, Biological 
Processes, Cellular Components, and Pathways. It was observed that the results are 95% 
similar and this validates the result obtained in this study. A KNN classifier achieves sample 
membership prediction by building a model, which is later assessed by performance 
parameters such as accuracy, sensitivity, and specificity etc. Also the Kaplan-Mier survival 
curve produced from GBM clinical data confirms that GBM is aggressive irrespective of 
sample types because it gives a median survival of less than 1 year. With the descriptions 
above, it can be concluded that the aims in this study were all met. However there could 
still be improvements to the methods adopted in this study for a better analysis outcome.  
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